[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 2 of 62 
 
Sponsor Information  
 
Sponsor Name & Legal 
Registered Address  
 GlaxoSmithKline Consumer Healthcare 
([LOCATION_006]) Trading Limited  
[ADDRESS_280086],  
Middlesex,  
TW8 9GS,  
[LOCATION_008] ([LOCATION_006])  
Sponsor Contact [CONTACT_1105] 
([COMPANY_004] CH)  
[ADDRESS_280087], Warren, NJ  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 3 of 62 
Document History  
 
Document  Version  Summary of Changes  
Original protocol  1.0 Not applicable (N/A)  
Amendment 1  2.0 Clarification throughout of 2 diaries being used, now 
labelled “washout diary” and “subject diary”.  
Amendment of Inclusion Criterion 5d to clarify that the 
less than 500ppb difference between samples 
requirement is between the 2 samp les collected at any 
timepoint.  
Correction to Table 6 -3 on pack for toothbrush.  
Correction in section 6.5 from “three study products” to 
“two study products”.  
Addition to section 6.[ADDRESS_280088] of 
country health authorities, institutional review boards/ethics committees ( IRBs/ECs), etc.   
 Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 4 of 62 
Principal Investigator [INVESTIGATOR_1061]  
• I confirm agreement to conduct the study in compliance with the protocol and any 
amendments according to the current International Conference on Harmonisation Good 
Clinical Practice (ICH GCP) guidelines.  
• I acknowledge that I am responsible for overall study conduct. I agree to personally 
conduct or supervise the described study.  
• I agree to ensure that all associates, colleagues and employees assisting in the conduct of 
the study are informed about their obligations. Mechanisms are in place to ensure site staff 
receives all appropriate information throughout the study.  
• I agree to conduct this study in full conformance with the laws and regulations of the 
country in whi ch the research is conducted and the Declaration of Helsinki.  
 
Investigator Name:   
[CONTACT_1216]:   
Investigator Signature:   
[CONTACT_1217]/Agreement:   
DD-Mmm -YYYY  
 Protocol  17 Sep 2022 | TMF-238323 | 2.0
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 5 of 62 
Table of Contents  
Sponsor Information  ................................ ................................ ................................ ............  2 
Document History  ................................ ................................ ................................ ...............  3 
Principal Investigator [INVESTIGATOR_1061]  ................................ ................................  4 
Table of Contents  ................................ ................................ ................................ ................  5 
1 PROTOCOL SUMMARY  ................................ ................................ ................................  10 
1.1 Synopsis  ................................ ................................ ................................ .................  10 
1.2 Schedule of Activities  ................................ ................................ ............................  13 
2 INTRODUCTION  ................................ ................................ ................................ .............  14 
2.1 Study Rationale  ................................ ................................ ................................ ...... 14 
2.2 Background  ................................ ................................ ................................ ............  15 
2.3 Benefit/Risk Assessment  ................................ ................................ .......................  15 
2.4 Mechanism of Action/Indication  ................................ ................................ ...........  [ADDRESS_280089] Restrictions  ................................ ...............................  23 
5.5.5  Medication and Treatment Restrictions  ................................ ................  23 
5.5.6  Contraception  ................................ ................................ ........................  23 
5.5.7  COVID -19 ................................ ................................ .............................  23 
5.6 Screen Failures ................................ ................................ ................................ ....... 23 
5.7 Sponsor’s Qualified Medical Personnel  ................................ ................................  24 
5.8 Clinical Assessor Qualifications  ................................ ................................ ............  24 
6 INVESTIGATIONAL/STUDY PRODUCTS ................................ ................................ ... 24 
6.1 Investigational/Study Product Supplies  ................................ ................................ . 24 
6.1.1  Medical Devices  ................................ ................................ ....................  26 
6.1.2  Dosage Form and Packaging  ................................ ................................ . 26 Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280090] Usage Errors  ................................ ................................ ............  27 
6.2.2  Overdose  ................................ ................................ ...............................  28 
6.3 Investigational/Study Product Storage  ................................ ................................ .. 28 
6.4 Investigational/Study Product Accountability  ................................ .......................  28 
6.4.1  Destruction of Investigational/Study Product Supplies  ........................  29 
6.5 Blinding and Allocation/Randomization  ................................ ...............................  29 
6.6 Breaking the Blind  ................................ ................................ ................................ . 30 
6.7 Compliance  ................................ ................................ ................................ ............  30 
6.8 Concomitant Medication/Treatment(s)  ................................ ................................ .. [ADDRESS_280091] 
DISCONTINUATION/WITHDRAWAL  ................................ ................................ .........  [ADDRESS_280092] Discontinuation/Withdrawal  ................................ ................................ ..... [ADDRESS_280093] to Follow up  ................................ ................................ ................................ ... 31 
8 STUDY PROCEDURES  ................................ ................................ ................................ ... 32 
8.1 Visit 1/Screening  ................................ ................................ ................................ ... 32 
8.1.1  Screening Procedures  ................................ ................................ ............  32 
8.2 Study Period  ................................ ................................ ................................ ..........  34 
8.2.1  Visit 2/Day 0 - Baseline  ................................ ................................ ........  34 
8.2.2  Visit 3/Week 3 (Day 21 +2)  ................................ ................................ .. [ADDRESS_280094] Examination  ................................ ................................ ..................  37 
9.1.2  OHT Examination  ................................ ................................ .................  37 
9.2 Efficacy Assessments  ................................ ................................ ............................  37 
9.2.1  Mouth Air VSC Determination  ................................ .............................  37 
9.2.2  Organoleptic Assessment of Oral Malodor  ................................ ...........  38 
9.3 Safety and Other Assessments  ................................ ................................ ...............  39 
9.3.1  Oral Soft Tissue (OST) Examination  ................................ ....................  [ADDRESS_280095] Tissue (OHT) Examination  ................................ ..................  39 
9.3.3  Pregnancy Testing  ................................ ................................ .................  39 
10 ADVERSE EVENT AND SERIOUS ADVERSE EVENTS  ................................ ...........  40 
10.1  Definition of an Adverse Event (AE)  ................................ ................................ .... 40 
10.2  Definition of a Serious Adverse Event (SAE)  ................................ .......................  41 
10.3  Time Period and Frequency for Collecting  AE and SAE Information  ..................  42 
10.4  Reporting Procedures ................................ ................................ .............................  42 
10.4.1  Reporting of an Adverse Event  ................................ .............................  43 Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 7 of 62 
10.4.2  Reporting of a Serious Adverse Event  ................................ ..................  43 
10.5  Evaluating Adverse Events  ................................ ................................ ....................  44 
10.5.1  Assessment of Intensity  ................................ ................................ ........  44 
10.5.2  Assessment of Causality  ................................ ................................ ....... 44 
10.6  Follow -up of AEs and SAEs ................................ ................................ ..................  45 
10.7  Withdrawal Due to an Adverse Event  ................................ ................................ ... 45 
10.8  Regulatory Reporting Requirements for SAEs ................................ ......................  45 
10.9  Pregnancy  ................................ ................................ ................................ ..............  46 
10.9.1  Time Period for Collecting Pregnancy Information ..............................  46 
10.9.2  Action to be Taken if Pregnancy Occurs  ................................ ..............  46 
10.10  Medical Device Incidents  ................................ ................................ ......................  46 
10.10.1  Definition of an Incident  ................................ ................................ ....... 47 
10.11  Reporting of Incidents and Malfunctions  ................................ ..............................  47 
10.12  Follow -up of Medical Device Incidents  ................................ ................................  48 
10.13  Regulatory Reporting Requirements for Medical Device Incidents ......................  48 
11 DATA MANAGEMENT  ................................ ................................ ................................ .. 48 
11.1  Case Report Form  ................................ ................................ ................................ .. 49 
11.2  Data Handling  ................................ ................................ ................................ ........  49 
11.2.1  Data Queries  ................................ ................................ ..........................  50 
11.3  Processing Patient Reported Outcomes  ................................ ................................ . 50 
12 STATISTICAL CONSIDERATIONS AND DATA ANALYSES  ................................ .. 50 
12.1  Sample Size Determination  ................................ ................................ ...................  50 
12.2  Populations for Analysis  ................................ ................................ ........................  51 
12.2.1  Definition of Analysis Populations  ................................ .......................  51 
12.2.2  Exclusions of Data from Analysis ................................ .........................  51 
12.3  Statistical Analyses  ................................ ................................ ................................  51 
12.3.1  Primary Analysis  ................................ ................................ ...................  51 
12.3.2  Secondary Analyses  ................................ ................................ ..............  52 
12.3.3  Safety Analysis  ................................ ................................ .....................  53 
12.3.4  Demographic and Baseline Characteristics  ................................ ...........  53 
12.3.5  Study Drug/Product Compliance and Use of Other Therapi[INVESTIGATOR_014]  .............  [ADDRESS_280096]/ Ethics Committee ................................ ..... [ADDRESS_280097] of the Study  ................................ ................................  55 Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280098] Usage Instructions Sheet  ................................ ................................ ..........  61 
15.2  ABBREVIATIONS  ................................ ................................ ...............................  62 Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280099] of in text tables  
Table 1 -1 Schedule of Activities  ................................ ................................ ...........  13 
Table 3 -1 Study Objectives and Endpoints  ................................ ...........................  16 
Table 6 -1 Investigational/Study Product Supplies  ................................ ................  [ADDRESS_280100] Supplies  ................................ ................................ .... 25 
Table 6 -3 Sundry Items  ................................ ................................ .........................  26 
Table 15 -1 Abbreviations  ................................ ................................ ........................  62 
  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 10 of 62 
1 PROTOCOL SUMMARY  
1.1 Synopsis  
Background and Rationale : 
This study will investigate the efficacy of an experimental dentifrice, containing 0.454% 
stannous fluoride and 0.3% zinc chloride, to reduce oral malodor, compared to a marketed 
regular fluoride dentifrice after [ADDRESS_280101]’s breath, and through the 
instrumental measurement of the concentration of volatile sulfur compounds (VSCs) of a 
sample of the subject’s breath.  
Objectives and Endpoints : 
Objectives  Endpoints  
Primary  
To evaluate and compare the change in morning 
oral malodor by [CONTACT_232166] 3 weeks of twice -daily tooth brushing  
using an experimental dentifrice containing 
0.454% stannous fluoride and 0.3% zinc 
chloride compared to a standard fluoride 
dentifrice . Change in mean o rganoleptic score  from 
Baseline (pre -brushing) to 3 weeks (pre -
brushing)  
Secondary  
To evaluate and compare the change in morning 
oral malodor by [CONTACT_232167] 3 
weeks of twice -daily tooth brushing using an 
experimental dentifrice containing 0.454% 
stannous fluoride and 0.3% zinc chloride 
compared to a stan dard fluoride dentifrice.  Change from Baseline ( pre-brushing) to 3 weeks 
(pre-brushing)  in:- 
• Mean t otal VSC concentration in breath.  
• Mean h ydrogen sulfide, methanethiol and 
dimethyl sulfide concentration in breath.  
To evaluate and compare the change in oral 
malodor post brushing following 3 weeks of 
twice -daily tooth brushing using an experimental 
dentifrice containing 0.454% stannous fluoride 
and 0.3% zinc chloride compared to a standard 
fluoride dentifrice.  Change from Baseline ( pre-brushing ) to 3 week s 
([ADDRESS_280102]-brushing ) in: 
• Mean t otal VSC concentration in breath.  
• Mean h ydrogen sulfide, methanethiol and 
dimethyl sulfide concentration in breath.  
• Mean breath organoleptic scores.  
To evaluate and compare the change in oral 
malodor [ADDRESS_280103] brushing following 3 weeks twice -daily 
use using an experimental dentifrice containing 
0.454% stannous fluoride and 0.3% zinc 
chloride compared to a standard fluoride  
dentifrice.  Change from pre -brushing to [ADDRESS_280104] 
brushin g at Baseline and after 3 weeks in: - 
• Mean t otal VSC concentration in breath.  
• Mean h ydrogen sulfide, methanethiol and 
dimethyl sulfide concentration in breath.  
• Mean breath organoleptic scores.  
Safety  
To assess the tolerability of an experimental 
dentifrice  containing 0.454% stannous fluoride 
and 0.3% zinc chloride  Treatment emergent adverse events  
 
  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 11 of 62 
Study Design : 
This will be a single center, single blind  (to the examiner s undertaking the oral malodor 
assessments ), randomized  (stratified by [CONTACT_1130]’s sex) , controlled, two  arm parallel study in 
volunteers  with clinically diagnosed gingivitis .  The study will evaluate the clinical efficacy of 
an experimental dentifrice containing 0.454% stannous fluoride and 0.3% zinc chloride to 
reduce oral malodor after 3 weeks of twice -daily use compared to a regular reference  dentifrice . 
Potential subjects will attend a screening visit to determine their suitability to participate.  
Having obtained their written informed consent, relevant details o f their medical history and 
current medications will be recorded .  Subjects will then undergo the screening assessment of 
their oral malodor followed by [CONTACT_1112] ( OST ) and oral hard tissue (OHT) examination s 
and an assessment s of gingivitis ( Bleedi ng on probing examination ).  Subjects with gingivitis 
and oral malodor per the inclusion criteria , as well as meeting all other study criteria, will be 
considered as eligible to proceed , appointed for baseline assessments  and dispensed a washout 
dentifrice and toothbrush to use instead of their regular oral hygiene products until they return 
for Visit 2 (1 -3 weeks after screening) . 
At the Baseline visit (Visit 2 ), subjects, having abstained from oral hygiene procedures and food 
consumption for at least [ADDRESS_280105]’s sex  and randomized to one 
of the two  study treatments.  Subjects will then be instructed on the use of their study products 
and will brush their teeth, under supervision, for 1 minute with their assigned dentifrice.  One 
hour (±5 minutes) post brushing, subjects will have their post -brushing  breath VSC and 
organoleptic assessments.  Subjects will then undergo an OST examination and instructed to 
brush twice daily (for 1 minute, morning and evening) with their assigned study dentifrice for 
the next 3 weeks until their next visit (Visit 3).  
At Visit 3, subjects, having abstained from oral hygiene procedures and food consumption for 
at least [ADDRESS_280106] 
and OHT examinations and exit the study.  
Study Products : 
Experimental Dentifrice  Reference  Dentifrice  
Dentifrice containing 0.454% stannous 
fluoride and 0.3% zinc chloride.  Standard  Fluoride Dentifrice [0.243% 
sodium fluoride]  
(Crest  Cavity Protection, US market)  
Both dentifrices will be brushed on to the teeth, twice daily (morning and evening) for 1 timed 
minute  in line with the usage instructions in Appendix 15.1 . 
Type and Planned Number of Subjects : 
Study subjects of either sex and any gender , aged of 18-65 years , will be in good general health  
with clinically diagnosed gingivitis and  with the level of oral malodor required at baseline to 
participate in the study.  
Sufficient  subjects will be screened to randomize approximately  106 subjects to study treatment 
(approximately 53 per treatment group) to  ensure approximately 100 evaluable subjects 
complete the study.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 12 of 62 
Statistical Analysis:  
For the primary endpoint analyse s, an ANCOVA model will be used to analyze the change in 
mean breath organoleptic score from Baseline (pre -brushing) to 3 weeks (pre -brushing)  with 
study product and gender as fixed effects and the mean Baseline (pre -brushing)  breath 
organoleptic score  as a covariate. The difference between least square means for the 
Experimental Dentifrice compared to the Reference Dentifrice will be used to test for a 
difference between products  at the two-sided 5% significance level . The assumption of 
normality and homogeneity of variance in the ANCOVA will be investigated. In case of 
violation of these assumptions, a suitable nonparametric test (adjusted for gender) will be 
performed, and results will be provided to support the ANCOVA results.  
For secondary endpoint  change from Baseline analyses, a similar ANCOVA model as used for 
the primary analysis will be applied but with the appropriate pre -brushing and post -baseline 
result used accordingly. For VSC endpoints, data will be log (base 10) transformed prior to 
analysis. There will be no adjustment for multiplicity  for secondary endpoints.  
 Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 14 of 62 
2 INTRODUCTION  
It is generally accepted that oral malodor primarily originates from bacterial putrefaction of 
proteinaceous and other compounds within the oral cavity particularly by [CONTACT_232168], Actinobacillus actinomycetemcomitans  and Prevotella 
intermedia  (Awano et al., 2002 ).  These bacteria are located throughout the oral cavity, and are 
found in particularly high numbers in saliva (Awano et al., 2002 ) and on the tongue, especially 
towards the tongue posterior  (Allaker et al., 2008 ).  These bacterial species are also associated 
and present in higher numbers in those with gingivitis and periodontal disease (Abusleme et al., 
2021 ) 
The odors that these bacteria produce include amines such as putrescine and cadaverine and 
fatty acids such as but yrate and valerate  (Van den Broek et al., 2007 ). However, a significant 
contributor to oral malodor are the volatile sulfur compounds (VSCs) such as hydrogen sulfide, 
methanethiol and dimethyl  sulfide, with hydrogen sulfide the most concentrated odor on the 
breath of oral malodor  sufferers  (Washio et al., 2005 ). 
Although management of oral malodor  is an active area of research, objective, clinical 
measurement of oral malodor , and thereby [CONTACT_232169] , is currently not possible. Organoleptic/hedonic assessment is often employed and 
clearly has the ben efit of simplicity and relevanc y to patients, however the human nose is not 
linear in response to malodor concentration and measurement is often complicated by [CONTACT_232170].  Measurement of VSC concentration in 
breath is therefore routinely used as a quantifiable surrogate measurement and given the 
prevalence of VSCs in breath this would appear to be appropriate. Indeed , clinical measurement 
of VSCs by [CONTACT_232171], the OralChroma and gas c hromatography (GC) 
have been used to provide clinical evidence of efficacy of treatments  (Vandeker ckhove et al., 
2009 , Oho et al., 2001 ). Moreover, Rosenberg et al.  have demonstrated a correlation between 
organoleptic assessment of oral malo dor and clinically measured VSC concentrations  
(Rosenberg et al., 1991a ). 
Whilst not yet conclusive, there is evidence that periodontal diseases  may be a factor in the 
etiology of oral malodor (De Geest et al., 2016 ).  Oral malodor has been  significantly related to 
periodontal pocket depth (Chen et al., 2016 ) and analysis of periodontal pockets has sho wn the 
presence of high concentrations of VSCs (Rizzo, 1967 ).  Additionally the bacterial species 
associated with gingivitis and periodontal dise ase are also implicated in oral malodor 
(Abusleme et al., 2021 ).   
Effective treatments to control oral malodor include mechanical removal of oral bacteria  and 
dental plaque , such as tongue scrapi[INVESTIGATOR_232151]/tooth brushing, and adjunctive use of 
antimicrobials such as chlorhexidine, cetylpyridinium chloride, esse ntial oils and zinc ions (De 
Geest et al., 2016 ). 
This study aims to assess the oral malodor of subjects with clinically diagnosed gingivitis  who 
use an experimental dentifrice containing both stannous fluoride and zinc ions compa red to use 
of a standard sodium fluoride dentifrice.  
2.1 Study Rationale  
This 3-week, randomized, controlled , parallel -design, stratified  clinical study  has been designed 
to evaluate the ability of an experimental dentifrice containing 0.454% stannous fluoride  and 
0.3% zinc chloride to reduce oral malodor, compared to a regular fluoride dentifrice  in a 
population with clinically diagnosed g ingivitis .   Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280107] is well 
established (see Section 2.2 ).  Additionally, the oral malodor benefits through use of a s ingle 
application  of zinc -containing dentifrices has also been demonstrated in a non -gingivitis 
population.  However, additional data are required to confirm the oral malodor reduction benefit 
of the experimental dentifrice in a population of subjects with clinically  diagnosed gingivitis.   
The study will inform on the efficacy of the experimental dentifrice to reduce oral malodor 
through usage over 3 weeks (in line with ADA guidelines for the testing of products used in the 
management of oral malodor (ADA, 2016 )). 
2.2 Background  
The experimental dentifr ice being tested contains stannous fluoride, an active with an extensive 
history of gum -health efficacy (Makin, 2013 , Paraskevas and Van der Weijden, 2006 , Twetman 
et al., 2003 , Rølla and Ellingsen, 1994 ).  Formulations containing the same concentration of 
stannous fluoride as  in the experimental dentifrice being evaluated in this study (although not 
containing zinc ions), have been evaluated previously both for dentine hypersensitivity relief 
(Parkinson et al., 2013 , Parkinson et al., 2015 , Parkinson et al., 2016 ) and improvements in 
gingivitis (Parkinson et al., 2018b , Parkinson et al., 2018a ).  Additionally this formulation has 
been shown not to exhibit dental staining that has previously been observed with stannous 
fluoride -based dentifrices (Nehme et al., 2013 ).  Stannous fluoride has been recognized as safe 
and effective for the treatment of gingivitis by [CONTACT_3133] (FDA) 
(FDA, 2003 ).  Additionally a 0.45% stannous fluoride dentifrice has been shown to reduce oral 
malodor using both VSC measurement and organolep tic assessment in a non -gingivitis healthy 
population (Gerlach et al., 1998 ). 
Given the association between gum disease and oral malodor (see Introduction) it is expected 
that treatment of gingivitis (through stannous fluoride) will addi tionally show benefits in oral 
malodor.  Additionally, z inc-containing products are highly effective  at reducing oral malodor 
(Young et al., 2001 , Schmidt and Tarbet, 1978 , Newby [CONTACT_2297]., 2008 , Payne et al., 2011 ), possibly 
because they are dual active, being both antimicrobial, and chemically reactive to VSCs  
resulting in non -volatile (and therefore non -odorous) sulfur species (Burnett et al., 2011 ). 
In summary, existing clinical data provide evidence of oral malodor efficacy for zinc -containing 
dentifrice formulations.  However there appears to be little published evidence on the efficacy 
of these formulations for those with  gingivitis.  This study will therefore  evaluate the efficacy 
of an experimental d entifrice containing stannous fluoride and zinc chloride in red ucing oral 
malodor in a population of subjects with clinically diagnosed gingivitis.  
2.3 Benefit/Risk Assessment  
Complete information  for th e experimental dentifrices may be found in the single re ference 
safety document (SRSD), which for this study is the Safety S tatement.  
Whilst the exact formulation of the experimental dentifrice under investigation ha s not been 
previously clinically tested, similar products containing stannous fluoride and zinc chloride 
have been evaluated in clinical studies (see Background Section 2.2 ).  These studies 
demonstrated the anti-gingivitis and/or anti oral malodor efficacy and safety of similar 
formulations.  The active ingredients and formulation excipi[INVESTIGATOR_232152] a  history of safe use in oral care products and are currently used in marketed 
daily use dentifrices . Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 16 of 62 
The experimental dentifrice  is considered generally safe for topi[INVESTIGATOR_1064], with twice daily 
brushing, under the controlled conditions of a clinical trial. 
2.4 Mechanism of Action/Indication  
This study will be conducted in generally healthy subjects with clinically diagnosed gingivitis 
and with a minimum level of clinically -measured oral malodor as described in the inclusion 
criteria.  The dentifrice being  evaluated contains zinc ions which are effective at reducing oral 
malodor through their antimicrobial activity coupled with their ability to chemically react with 
VSCs  resulting in non -volatile (and therefore non -odorous) sulfur species (Burnett et al., 2011 ).  
Additionally, the stannous fluoride in the formulation is expected to provide oral malodor 
benefits through its antimicrobial/ antiplaque benefits (Bosma et al., 1997 , Mankodi et al., 2005 , 
Mallatt et al., 2007 ) leading to improvements in gingivitis (Parkinson et al., 2018a , Parkinson 
et al., 2018b ). 
3 STUDY OBJECTIVES AND ENDPOINTS  
Table 3-1 Study Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To evaluate and compare the change in morning 
oral malodor by [CONTACT_232166] 3 weeks of twice -daily tooth brushing  
using an experimental dentifrice containing 
0.454% stannous fluoride and 0.3% zinc 
chloride compared to a standard fluo ride 
dentifrice . Change in mean o rganoleptic score  from 
Baseline (pre -brushing) to 3 weeks (pre -
brushing)  
Secondary  
To evaluate and compare the change in morning 
oral malodor by [CONTACT_232167] 3 
weeks of twice -daily tooth brushing using an 
experimental dentifrice containing 0.454% 
stannous fluoride and 0.3% zinc chloride 
compared to a standard fluoride dentifrice.  Change from Baseline ( pre-brushing) to 3 weeks 
(pre-brushing)  in:- 
• Mean total VSC concentration in breath.  
• Mean hydrogen sulfide,  methanethiol and 
dimethyl sulfide concentration in breath.  
To evaluate and compare the change in oral 
malodor post brushing following 3 weeks of 
twice -daily tooth brushing using an experimental 
dentifrice containing 0.454% stannous fluoride 
and 0.3% zinc  chloride compared to a standard 
fluoride dentifrice.  Change from Baseline ( pre-brushing ) to 3 weeks 
([ADDRESS_280108]-brushing ) in: 
• Mean total VSC concentration in breath.  
• Mean hydrogen sulfide, methanethiol and 
dimethyl sulfide concentration in breath.  
• Mean b reath organoleptic scores.  
To evaluate and compare the change in oral 
malodor [ADDRESS_280109] brushing following 3 weeks twice -daily 
use using an experimental dentifrice containing 
0.454% stannous fluoride and 0.3% zinc 
chloride compared to a standard fluoride  
dentifrice.  Change from pre -brushing to [ADDRESS_280110] 
brushing at Baseline and after 3 weeks in: - 
• Mean total  VSC concentration in breath.  
• Mean hydrogen sulfide, methanethiol and 
dimethyl sulfide concentration in breath.  
• Mean breath organoleptic scores.  
Safety  
To assess the tolerability of an experimental 
dentifrice  containing 0.454% stannous fluoride 
and 0.3% zinc chloride  Treatment emergent adverse events  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 17 of 62 
This study will be considered successful if the experimental dentifrice containing stannous 
fluoride and zinc chloride demonstrates statistically significant greater reduction in total breath 
VSC compared to the reference dentifrice following 3 weeks of twice daily brushing.  
4 STUDY DESIGN  
4.1 Overall Design  
This will be a single center, single blind  (to the examiner s undertaking the oral malodor 
assessments ), randomized  (stratified by [CONTACT_423]’s sex) , controlled, two  arm parallel study in 
volunteers  with clinically diagnosed gingivitis  and oral malodor.  The study will evaluate the 
clinical efficacy of an experimental dentifrice containing 0.454% stannous fluoride and 0.3% 
zinc chloride to reduce oral malodor after [ADDRESS_280111] 8  hours .  Having 
obtained their written informed consent, relevant detail s of their medical history and current 
medications will be recorded, followed by [CONTACT_232172].  
Subjects will then undergo oral soft tissue (OST) and oral hard tissue (OHT) examinations,  and 
a gingivitis  assessment (bleedi ng on probing  examination ).  Subjects with sufficient  gingivitis 
and sufficient concentration of hydrogen sulfide  in their breath  as per the inclusion criteria , as 
well as meeting all other study criteria, will be considered as eligible to proceed , appoint ed for 
baseline assessments  and dispensed a washout dentifrice and toothbrush to use instead of their 
regular oral hygiene products until they return for Visit 2 (1 -3 weeks after screening) .  A 
washout diary will also be dispensed for the subjects to record their washout product usage.  
At the Baseline visit (Visit 2) subjects, having abstained from oral hygiene procedures and food 
consumption for at least 8  hours,  will undergo baseline breath VSC (using the OralChroma 
instrument) and organoleptic asses sments (judged by a panel of 3 assessors using the hedonic 
scale of Rosenberg (Rosenberg et al., 1991b ).  The organoleptic panel will have been recently 
calibrated and standardized (within th e past year) with a kappa statistic of ≥0.6 per the American 
Dental Association guidelines (ADA, 2016 ). 
Qualifying subjects, having a hedonic score ≥2 and a mean concentration of hydrogen sulfide 
(a major contributor to oral malodor) in their breath of at least 150ppb, will be stratified by [CONTACT_1560]’s sex and randomized to one of the [ADDRESS_280112] diary and will brush their teeth, under supervision, 
for 1 timed minute with their assigned dentifrice.  One hour (±5 minutes) post brushing, subjects 
will have their post -brushing breath VSC and organoleptic assessments , followed by [CONTACT_232173] .  Subjects will be instructed to brush twice daily (for 1 minute, morning and 
evening) with their assigned study dentifrice for the next 3 weeks (+ 2 days) until their next 
visit (Visi t 3).  
At Visit 3, subjects, having abstained from oral hygiene procedures and food consumption for 
at least [ADDRESS_280113] and OHT examinations and exit the study.  
Safety and oral tolerability of the study products will be monitored over the 3 -week usage period 
by [CONTACT_1125].  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 18 of 62 
4.2 Scientific Rationale for S tudy Design  
A parallel group experimental design was selected as carryover effects from the treatment 
groups would be anticipated.  
According to the International Conference on Harmonisation (ICH) guidelines (ICH, Nov 
2016 ), for a study to be classified as truly double -blind, not only does the examiner (and any 
appropriate member of staff who may be involved in the dispensing of products, analysis of 
data etc.) n eed to be blind to the treatment a subject receives, but the products under test must 
be identical in every way (color, flavor, appearance, packaging).  Given the experimental 
dentifrices and the reference dentifrice will differ in appearance and flavor, t he level of 
blindness for this study is described as ‘examiner blind’ . Study dentifrices  will be supplied in 
overwrapped  tubes. The blind will be maintained by [CONTACT_232174], brushing 
instruction and  supervised brushings not being involved i n the clinical examinations and  study 
products being provided to subjects in blinded packs.   Dental examiner (s) and organoleptic 
assessors  will be blind to treatment allocation to ensure there is no bias in the assessments.  
This is a single -center study.  The same examiner (s) will perform the clinical assessments 
throughout the study to reduce  the possibility of inter -examiner variability.  
A regular fluoride dentifrice has been selected as  reference dentifrice .  For the purposes of this 
study, it was deemed  more relevant to compare the efficacy of the experimental dentifrice 
against breath odor reducing performance of a typi[INVESTIGATOR_232153] -use dentifrice rather than a placebo.  
The assessments  used in this study (VSC determination and organoleptic assessment) are w ell 
established and recognized in the scientific literature for the evaluation of oral malodor (Rösing 
and Loesche, 2011 , ADA, 2016 ).  The odor judges performing the organoleptic assessment 
should have been recently calibrated and standardized with a  kappa statistic of ≥0.6 per the 
ADA guidelines (ADA, 2016 ).  VSC determination will be performed using the OralChroma 
instrument (Tangerman and Winkel, 2008 ), a methodology which has been previously well 
correlated with hedonic assessment (Dadamio et al., 2013 ) and Gas Chromatographic 
assessment of VSCs (Murata et al., 2006 ).  In line with recommendations, the instrument will 
have been calibrated by [CONTACT_232175] (Tangerman and 
Winkel, 2008 ).  Organoleptic assessment of the hedonics of oral malodor will be perfo rmed 
using the scale devised by [CONTACT_232176] (Rosenberg et al., 1991b ).  This scale has been used in 
many previous clinical studies including demonstration of the efficacy of oral healthcare 
products in the reduction of  oral malodor (Winkel et al., 2003 ). 
A wash -out period  where the subjects use a standardized dentifrice prior to baseline, is required 
to standardi ze oral hygiene procedures and products prior to oral malodor assessments since 
some oral hygiene products  can affect oral malodor.  
Oral malodor develops from the breakdown by [CONTACT_84798] -organisms of various proteins in the 
mouth.  In order to for oral malodor of a sufficient level is present to be detected and treated, 
subjects will be asked to abstain from performing oral hygiene procedures and eating for at least 
[ADDRESS_280114] differences in oral malodor following use of study products , it is necessary, at the 
baseline visit  (pre-brushing) , that subjects have a minimum level of oral malodor as me asured 
by [CONTACT_232177], and the hydrogen sulfide concentration in their breath ( both as 
defined in the inclusion criteria).  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 19 of 62 
The experimental dentifrice being tested is intended to be indicated for users with gingivitis.  
This study will therefore  assess oral malodor in  subjects with clinically measurable levels of 
gingivitis, defined as those with 10-30 % bleeding sites on probing  (Chapple et al., 2018 ).   
Gingivitis symptoms are known to vary across the menstrual cycle (Machtei et al., 2004 ).  
Additionally, the production of breath VSC is influenced by [CONTACT_232178]  (Calil et al., 2008 , 
Tonzetich et al., 19 78).  Subjects will therefore be stratified by [CONTACT_423]’s sex prior to 
randomization to ensure equal balance of females in both treatment arms.   Whilst this approach 
will not completely resolve within subject variation due to menstrual cycle, randomi zation will 
help ensure subjects at different stages of their menstrual cycle will be evenly distributed across 
the two treatment groups.  
The testing duration of [ADDRESS_280115] use is aligned with recommendations provided by [CONTACT_232179] n for the testing of products for the management of oral malodor 
(ADA, 2016 ). 
Whilst the study products are not contra -indicated for pregnancy (their use would not be 
expected to cause harm either to the mother or foetus), pregnant females will be excluded from 
this study due to the increased prevalence and severity of gingivitis (Samant et al., 1976 ) which 
could be a confounding factor for the objectives of this study.  Pregnant females and those 
intending to become pregnant  will be excluded.  Pregnancy will be monitored by [CONTACT_1130] -
reported pregnancy status.  
4.3 Justification for Dose  
Subjects will use their assigned dentifrices twice daily in agreement with recommendations 
provided by [CONTACT_232180] (ADA, 2022 ).  The 
brushing time has been standardized as 1 minute in line with normal consumer practice 
(Macgre gor and Rugg ‐Gunn, 1985 , Ganss et al., 2009 ) and to align with previous oral malodor 
studies performed by [CONTACT_456] . 
On each brushing occasion, the toothbrush will be dosed with a ribbon of dentifrice (covering 
the entire length of the toothbrush), in line with the proposed product labelling for the 
experimental dentifrices and the current product labelling f or the marketed reference dentifrice.  
No dose modification is permitted in this study.  Any variation from the product usage 
instructions should be communicated to study site personnel and recorded as a deviation.  
4.[ADDRESS_280116] visit date . 
5 STUDY POPULATION  
5.1 Type and Planned Number of Subjects  
Volunteers of either sex and any gender, aged 18 – 65 years will be recruited with sufficient 
levels of oral malodor (as defined in the inclusion criteria) to allow for evaluation of change Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 20 of 62 
(reduction)  in these parameters during the study.  Subjects will be recruited from the study site’s 
database.  
Sufficient subjects will be screened to randomize approximately 106 subjects  (equally 
distributed across the two treatment groups) to ensure approximately [ADDRESS_280117] eligibility to participate in the clinical study should be reviewed and documented by [CONTACT_1131]’s study team be fore subjects are included in the study.  
5.[ADDRESS_280118] meet all the following inclusion criteria to be eligible for enrollment into, 
and continuance in the study:  
1. Provision of a signed and dated informed consent document indicating that the subject has 
been informed of all pertinent aspects of the study before any assessment is performed.  
2. Subject is of either sex and any gender who, at the time of screening, is between the ages 
of [ADDRESS_280119] in good general and mental health with, in the opi[INVESTIGATOR_1066], no clinically significant or relevant abnormalities in medical 
history (for example, a medical condition or medication confirmed to contribute to 
xerostomia) ,or upon oral examination , that would impact the subject’s safety, wellbeing or 
the outcome s of the study, if they were to parti cipate in the study, or affect the subject ’s 
ability to understand and follow study procedures and requirements . 
5. Subject with generally good oral health that fulfil all of the following:  
a. Having at least 20 natural  (vital) teeth.  
b. Good oral health without le sions in the oral cavity (including the tongue) that could 
interfere with the study evaluations . 
c. Having clinically  diagnosed,  plaque -induced gingivitis defined as having 10 -30 % 
bleeding sites  from the bleeding on probing assessment . 
d. At Screening (Visit 1) and prior to brushing with assigned dentifrice  at Baseline 
(Visit 2) s ubjects must provide [ADDRESS_280120] be ≤500ppb 
difference in hydrogen sulfide between the [ADDRESS_280121] be ≤500ppb difference in hydrogen sulfide between the 2 
samples collected at baseline (pre -brushing).  
e. At Baseline (Visit 2), prior to brushing with assigned dentifrice subjects  must 
provide a breath sample with a mean organoleptic score ≥2.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 21 of 62 
5.3 Exclusion Criteria  
An individual who meets any of the following exclusion criteria will be excluded from the 
study:  
1) Subject who is an employee of the investigational site, either directly inv olved in the 
conduct of the study or a member of their immediate family; or an employee of the 
investigational site otherwise supervised by [CONTACT_093]; or a n employee of the 
sponsor directly involved in the conduct of the study or a member of their i mmediate 
family.  
2) Subject who has participated in other studies (including non -medicinal studies) involving 
investigational product(s) within 30 days of study entry and/or during study participation  
or who has pr eviously been enrolled in this study.  
3) Subject  with, in the opi[INVESTIGATOR_1068],  an acute or 
chronic medical or psychiatric condition or laboratory abnormality that may increase the 
risk associated with study participation or study  product administration or may interfere 
with the interpretation of study results and, in the judgment of the investigator or 
medically qualified designee, would make the subject inappropriate for entry into this 
study.  
4) A subject who is pregnant (self -reported) or intending to become pr egnant during  the 
study  
5) Subject who is  breastfeeding.  
6) Subject who habitually smokes, uses tobacco products or who vapes.  
7) Subject with known or suspected intolerance or hypersensitivity to the study products  or 
any of their stated ingredients (or closely related compounds).  
8) Subject who is unwilling or, in the opi[INVESTIGATOR_1069], unable to comply with the requirements and/or Lifestyle Considerations  of the 
study.  
9) Subject with a recent history (within the last year) of alcohol or other substance abuse.  
10) General medical exclusions:  
a) Subject with a m edical history that may prevent the subject from participating in the 
study unt il study conclusion.  
b) Subject with,  or having recent history of , bronchitis, tonsillitis or sinusitis (within 6 
weeks)  or any other systemic condition that can cause oral malodor eg. xerostomia, 
chronic acid reflux, Type 1 diabetes, Crohn’s disease, celiac disease or liver/kidney 
conditions.  
c) Subject with  a significant infectious disease, such as hepatitis, COVID -19, flu, 
respi[INVESTIGATOR_4416], tuberculosis, or any other condition which can be transmitted in 
saliva or salivary aerosols  which, in the opi[INVESTIGATOR_1649] o f the examiner, could endanger the 
organoleptic assessors . 
d) Subject with any condition that impacts gum health ( e.g. Type 2 Diabetes).  
11) General medication exclusions : 
a. Subject using any antibiotic  medication  within [ADDRESS_280122] using  chlorhexidine , cetylpyridinium chloride (CPC) or stannous fluoride 
containing mouthwash or dentifrice within 14 days prior to Visit 2 or between Visit 2 
& 3. Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280123] oral mouth odour ( e.g. Diazepam, 
Alprazolam, Lorazepam etc).  
12) General oral exclusions:  
a. Subject with o rthodontic or prosthetic appliances (fixed or removable), including 
dental implants.  
b. Subject having had professional dental cleaning (oral prophylaxis) within [ADDRESS_280124] with signs of active periodontal disease (with probing depth >3mm)  or who 
is receiving or has received treatment for periodontal disease (including surgery) 
within [ADDRESS_280125] of the study (for example, stomatitis, 
open sores, lesions, cavitied caries lesions, redness or swelling.  
h. Subject who does not practice daily oral care.  
13) Subject with oral malodor which, in the opi[INVESTIGATOR_871], is not expected to  
respond to treatment with an over -the-counter dentifrice.  
14) Subject who, in the opi[INVESTIGATOR_871], should not participate in the study.  
5.4 Randomization Criteria  
Subjects who satisfy the study selection criteria will be stratified according to their sex  (male 
or female) and randomized to study treatment .  
5.[ADDRESS_280126] subjects to remind them of lifestyle restrictions and approaching scheduled 
visits. 
5.5.1  Oral Hygiene Restrictions  
• Visits 1 -3:  
• Subjects will be asked to delay elective dental treatment (for example, dental 
prophylaxis) for the duration of the study. They will be required to inform site 
staff of any emergency treatment they r eceive during the study . 
• Subjects should not use any other oral care products (e.g. dentifrices, mouthwash, 
dental floss, interdental brushes, toothpi[INVESTIGATOR_103483], water pi[INVESTIGATOR_103483], breath freshening 
products, e.g. chewing gums, breath mints, cough drops or breath spray s etc.) 
other than those provided during the study.  
• Subjects will not be permitted to use tongue brushes /scrapers  and should refrain 
from brushing or debriding their tongue for the duration of the study.  
• Visits 2  & 3: Subjects will abstain from all oral hygiene procedures for at least 8 
hours  prior to their visit to site . Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 23 of 62 
5.5.2  Dietary Restrictions  
• Visits 2 & 3:  
• Subjects will abstain from eating and drinking (with the exception of small 
amounts of water required for taking medication or to relieve thirst) for at least 8 
hours  prior to and during their clinical/instrumental assessment visits.  
• Subjects should refrai n from eating heavily spi[INVESTIGATOR_232154], garlic, and onion and 
drinking alcohol for at  least 24 hours  prior to the visit.  Subjects who present 
with external odors (e.g., alcohol, garlic, smoke, candy, perfume etc.) which may 
interfere with the study evaluation may be withdrawn from the study or may be 
asked to return to the site on another occasion.  
5.5.3  Use of Cosmetics  
• Visits 2 & 3:  Subjects will attend site without wearing cosmetic products that could 
affect the organoleptic assessments, e.g. perfume, lipstick etc . 
5.5.[ADDRESS_280127] Restrictions  
• Visits 1 -3: Subjects will not be permitted to smoke, vape or use tobacco products  from 
11pm the evening prior to attending the study site till after all clinical procedures have 
been completed for that visit . 
5.5.5  Medication and T reatment Restrictions  
• Visits 1 -3: Subjects will be asked to delay elective dental treatment (for example, 
dental prophylaxis) for the duration of the study. They will be required to inform site 
staff of any emergency treatment they receive during the study . 
• Visits 2  & 3: Subjects will be asked to inform site staff of changes to their 
medications/treatments for the duration of the study. Should a subject commence a 
course of medication which, in the opi[INVESTIGATOR_1069] , could impact study outcomes, the subject may be withdrawn.  
5.5.6  Contraception  
There are no contraception requirements for subjects participating in this study.  At each visit, 
female subjects of child -bearing potential should verbally confirm they are not cur rently 
pregnant or planning to become pregnant.  
5.5.7  COVID -19 
In accordance with the clinical site procedures , and at the investigator’s discretion , subjects may 
be required to provide a negative C OVID  test (PCR or later al flow test) and/or a temperature 
assessment prior to or while attending a study visit.  
5.6 Screen Failures  
Screen failures are defined as subjects who consent to participate in the clinical study but are 
not subsequently randomized.  To ensure transparent reporting of scre en failure subjects, a 
minimal set of screen failure information will  be collected,  includ ing demography, reason for 
screen failure (e.g. withdrawal of consent), eligibility criteria, any protocol deviations and any 
adverse events or incidents as applicabl e.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 24 of 62 
Individuals who do not meet the criteria for participation in this study (screen failure) may not  
be re -screened.  
5.7 Sponsor’s Qualified Medical Personnel  
Contact [CONTACT_1133]'s appropriately qualified medical/dental personnel for the 
study  is documented in the  Study Contact [CONTACT_1134].  
The contact [CONTACT_1135]/ dental questions 
or problems in the event that the established com munication pathways between the study site 
and the sponsor’s study team are not available.  
The contact [CONTACT_65369].  To facilitate access to 
appropriately qualified medical/dental personnel on study -related medic al/dental questions or 
problems, subjects will be provided with a contact [CONTACT_1137].   The contact [CONTACT_1138], as a 
minimum, protocol identifiers, the subject’s study identification number, contact [CONTACT_1139], and contact [CONTACT_232181] e event that the study  site cannot be reached to provide 
advice on a medical question or problem identified by a healthcare professional other than the 
investigator.  
5.8 Clinical Assessor Qualifications  
Clinical examiner (s) involved in the screening, safety a nd efficacy assessments will be 
appropriately qualified dental professionals, registered to practice in the US.  
Oral examinations to determine subject eligibility and to monitor the safety /performance of 
study products will be performed by [CONTACT_228955] t rained clinical examiner(s), with prior 
relevant clinical experience.  Clinical examiners performing the organoleptic assessments will 
have been recently calibrated and standardized with a kappa statistic of ≥0.6 . 
6 INVESTIGATIONAL/STUDY PRODUCTS  
For the pur poses of this study, per International Conference on Harmonization (ICH) 
guidelines, and the sponsor’s  policy, study intervention is defined as any investigational 
intervention(s), marketed product(s), placebo, or medical device(s) intended to be administe red 
to a study participant according to the study protocol.  
This includes a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way different from the approved form, or when used for an unapproved 
indication, or when  used to gain further information about an approved use.  
6.1 Investigational/Study Product Supplies  
The following study products will be supplied by [CONTACT_1142]’s Clinical Supplies Group.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 25 of 62 
Table 6-1 Investigational/Study Product Supplies  
Product 
Description  Experimental  
Dentifrice  Reference  Dentifrice  
0.454% Stannous Fluoride  dentifrice 
with 0.3% Zinc Chloride  Regular Fluoride Dentifrice  
Product Name  N/A Crest Cavity Protection (US 
Market Product)  
Pack Design  One carton containing 2 overwrapped tubes of dentifrice  
Dispensing 
Details  Visit 2 (Baseline): [ADDRESS_280128] Master 
Formulation 
Code (MFC)   N/A 
Dose/ Product 
Application  Subjects will dose the toothbrush provided with a ribbon of paste to cover 
the brush head (a full brush head) on each brushing occasion  
Route of 
Administration  Oral topi[INVESTIGATOR_232155] (morning and evening) for [ADDRESS_280129] to be returned to the sponsor.  
 
The following su ndry items  will be supplied by [CONTACT_456]’s Global Clinical Supplies Group.  
Table 6-[ADDRESS_280130] Name  [CONTACT_232203] (US Marketplace)  
Pack Design  One carton containing [ADDRESS_280131] Master Formulation Code (MFC)   
Dose/Application  Full ribbon of toothpaste on head of toothbrush 
provided  
Route of Administration  Topi[INVESTIGATOR_232156] a day (morning and 
evening)  
Return Requirements  All used/unused samples to be returned  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
CCI
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 26 of 62 
Table 6-3 Sundry Items  
Item Pack Design  Dispensing 
Details  Return/Disposal Details  
Used Samples  Unused 
Samples  
Sensodyne Sensitive 
Care soft -bristled 
Toothbrushes (US 
marketplace)  Individual 
toothbrush  Visit 1:  
1 brush  
Visit 2:  
1 brush  Destroy at site 
using site 
disposal 
procedures  Return  to 
sponsor  
Countdown Timer  Individual 
supplied in 
commercial pack  At V isit 2:  
[ADDRESS_280132]/study supplies for the accountability checks 
and subsequent destruction which will be provided by [CONTACT_1143].  
6.1.1  Medical Devices  
The toothbrushes to be u sed in this study are medical devices . 
6.1.2  Dosage Form and Packaging  
The study products are dentifrices, intended for topi[INVESTIGATOR_1064], and will be applied by 
[CONTACT_1144] a manual toothbrush . 
The experimental dentifrices will be manufactured and filled  into plain white tubes by [CONTACT_103]; the reference dentifrice will be supplied in its commercial pack. All study dentifrices 
will be overwrapped in white vinyl (to mask their identity and obscure the branding of the 
marketed product) with a study label affixed. The content of the product labels will be in 
accordance with all applicable regulatory requirements and will be the responsibility of the 
sponsor’s Global Clinical  Supplies Group. Each study label will contain, but not be limited to, 
protocol numb er, directions for use and storage requirements.  
Each subject  will receive sufficient tubes of their  assigned study dentifrice  for usage during the 
3-week treatment period. Washout dentifrice and s undry items will be supplied in their  
commercial packaging  for dispensing by [CONTACT_1145] 6.[ADDRESS_280133] and legible for the duration of the 
study. Subjects should be instructed to not remove or deface any part of the study label.  
All products supplied are for use only in this clinical study and should not be used for any other 
purpose.  
6.1.3  Preparation and Dispensing  
Subjects will be assigned to study treatment  in accordance with the randomization schedule 
generated by [CONTACT_232182], prior to the start of the study, using validated 
software.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280134], by [CONTACT_1146].  These staff members will 
not be involved in any safety/product performance assessments or any other aspect of the study 
that could be influenced by [CONTACT_1147] a subject has been assigned to.  An 
additional member of the site staff will verify the dispensing procedure has been completed 
accurately for each subject.  
6.[ADDRESS_280135] be stored in a secure, 
environmentally controlled, and monitored (manual or automated) area in accordance with the 
labeled storage conditions with access limited to the authorized site staff only.  
Subjects will be  instructed to self -administer their assigned study dentifrice according to the 
usage instructions provided to the subject.  Additionally, subjects will undergo supervised 
brushing at Visits 2&[ADDRESS_280136] ent with the intended label 
instructions.  
To help ensure subjects understand the amount of dentifrice  they should use each time they 
brush , brushing  instructions  and diary completion requirements : 
• staff will demonstrate dispensing a full ribbon of dentifri ce along the length of the  
toothbrush head to each randomized  subject and supervise their first brushing with study 
dentifrice and  diary completion.  
On-site administration  of study products will also be recorded in the CRF.  
Instructions on usage of the study products are detailed in the Section 15.[ADDRESS_280137] 8 hours prior to attending site at 
Visits 2&3.  
6.2.[ADDRESS_280138] usage  errors may result, in this study, from the administration or 
consumption of:  
• the wrong product,  
• by [CONTACT_1148],  
• at the wrong time,  
• or at the wrong dosage.  
Such errors occurring to a study subject are to be captur ed in the CRF.  In the event of a product 
usage  error, the sponsor should be notified immediately and under no circumstance should 
this exceed [ADDRESS_280139] usage  errors are reportable irrespective of the presence of an associated AE, including:  
• Usage errors involving subject exposure to any of the study products;  
• Potential product  errors or uses outside of what is foreseen in the protocol that do or 
do not involve the participating subject.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280140] usage  error is accompanied by [CONTACT_1149], as det ermined by [CONTACT_093], the 
usage  error and, any associated adverse event(s) are to be captured in the CRF AE form.  
6.2.[ADDRESS_280141] at an amount higher than 
specified in the protocol.  
Overdose is not likely to occur in this study.  
Overdose per se is not an AE. However, any clinical sequelae of an overdose should be reported 
as an AE (and serious adverse event (SAE), if appropriate). For reporting, follow the AE and 
SAE reporting instruc tions.  
6.3 Investigational/Study Product Storage   
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study products received and any discrepancies are reported and 
resolved before use accord ing to the supplied shippi[INVESTIGATOR_1074].  
The investigator, or designee, will ensure that all study products are stored in a secured, 
environmentally monitored (manual or automated) area with controlled access (authorized site 
staff only) in accordance w ith the labeled storage conditions and Clinical Study Supplies 
Checklist , and in accordance with applicable regulatory requirements.  
Site systems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily minimum and maximu m temperatures for all site storage locations (as 
applicable, including frozen, refrigerated, and/or room -temperature products).  This should be 
captured from the time of first product receipt throughout the study.  Even for continuous 
monitoring systems, a log or site procedure that ensures active daily evaluation for excursions 
should be available.  The operation of the temperature -monitoring device and storage unit (for 
example, refrigerator), as applicable, should be regularly inspected to ensure it is maintained in 
working order.  
Any excursions from the product -label storage conditions should be reported to appropriate site 
staff upon discovery and communicated to sponsor as soon as possible.  The site should actively 
pursue options for returning the p roduct to the storage conditions as described in the labeling, 
as soon as possible.  Excursions from the storage requirements, including any actions taken, 
must be documented as a protocol deviation and reported to the sponsor.  
Once an excursion is identif ied, the affected product (or products) must be quarantined and not 
used until the sponsor provides documentation of permission to use. Use of any of the affected 
product(s) prior to sponsor approval will be considered a protocol deviation.   
Site staff wi ll instruct subjects on the proper storage requirements for all take -home products.  
6.4 Investigational/Study Product Accountability  
All products supplied are for use only in this clinical study and should not be used for any other 
purpose.  
All study products  must be received by a designated person at the study sites, handled and stored 
safely and properly, and kept in a secured location to which only authorized site  staff have 
access. Upon receipt, all study products should be stored according to the instruct ions specified Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280142] supplies. All study products will be accounted for using the 
investigational/study product accountability form/record. The investigator is resp onsible for 
study product accountability, reconciliation, and record maintenance.  
Subjects should return their used and unused study products to the clinical site at Visits [ADDRESS_280143] accounta bility will be performed by [CONTACT_1150].  
6.4.1  Destruction of Investigational/Study Product Supplies  
At the end of the study, the Principal Investigator [INVESTIGATOR_1075], and a 
representative of the sponsor  (study monitor) will inventory all used and unused study products 
and sundry items.  The study product accountability record for returned study products will then 
be completed. All study product (used and unused) for this clinical study will be returned for 
destruction to the sponsor’s  Clinical Supplies Group  or designated vendor using the return 
instructions provided. Detailed instructions for the return of study product/study supplies for 
the accountability checks and subsequent destruction wil l be provided by [CONTACT_1151].  
6.5 Blinding and Allocation/Randomization  
All subjects will be centrally randomized to one of the t wo study products using an Interactive 
Response Technology (IRT). Before the stu dy is initiated, training, login information and 
directions for the IRT will be provided. Study products will be dispensed according to the 
instruction received through the IRT at the appropriate study visits.  
Returned study products should not be re -dispe nsed to any subject.  
The investigator’s knowledge of the product allocation should not influence the decision to 
enroll a subject or affect the order in which subjects are enrolled.  
This study is described as single -blind (the clinical examiner (s) performi ng the efficacy 
assessments will be blinded to the product received).  To ensure the examiner (s) remains 
blinded throughout the study, the examiner (s) will not be permitted in any area where study 
product is stored,  dispensed, or in use ; staff involved in the preparation and dispensing of study 
products will work in a separate area , and s ubjects will be instructed not to remove study 
products from the opaque bags provided/cartons outside of the dispensing room, while at the 
study site. Dispensing staff will  not be involved in any efficacy/safety assessment procedures 
during the study.  
Site staff, study statistician (s), data management staff  and other  employees of the sponsor and 
vendors acting on behalf of the sponsor, who may influence  study outcomes will b e blinded to 
the product allocation . 
Prior to randomization, subjects will be stratified on their sex as detailed in Section 5.4 . Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280144]’s product assignment is warranted. Subject safety must always be the first consideration 
in making such a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every effort to contact [CONTACT_1152] a subject’s 
product assignment unless this could delay emergency treatment of the subject.  
If a subject’s product assignment is unblinded, the sponsor must be notified within [ADDRESS_280145] ( IRB) if the blind is broken.  
6.[ADDRESS_280146] usage requirements :  
• First use of their assigned study dentifrice will be carried out under supervision at the 
study site at the baseline visit ( Visit 2 ); study  staff will demonstrate the correct amount 
of dentifrice to dispense and how to use the timer to ensure a 1-minute brushing time. 
A further supervised brushing will be carried out at the study site at Visit 3 . 
• Subjects will be provided with a diary at screening  (Visit 1) to record each completed 
brushing with washout and study product s. 
• Subjects will attend Visits 2&3 with all tubes of dentifrice  provided (used and unused) 
for a visual check of product usage, and w ith their completed diary for review by  [CONTACT_38992].  Any suspected over or under use, the number of any missed or additional brushings 
will be documented as deviations in the CRF ; subjects will be re -instructed in the correct 
use of product and diary compl etion, as required.  
• Subjects will also use the diary to note any issues with their study product, any oral 
problems, illnesses and new medications/ treatments. Details relevant to safety or 
efficacy should be reviewed by [CONTACT_093] (or suitably quali fied designee) and 
transcribed to the CRF, as appropriate; AEs must be documented in the CRF.  
The number of any missed or additional applications or doses will be captured as protocol 
deviations. Subjects will be re -instructed in the correct usage require ments and diary completion 
as needed.  
A record of the number of dentifrice tubes  dispensed to and taken by [CONTACT_232183]. Intervention start 
and stop dates, including dates for  intervention delays and/or dose reductions will also be 
recorded in the CRF.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 31 of 62 
6.8 Concomitant Medication/Treatment(s)  
Any medications, treatments or vaccine (including over -the-counter or prescription medicines, 
vitamins, and/or herbal supplements) taken durin g the study, from signing the informed consent, 
must be recorded in the CRF with indication, reason for use, unit dose, daily dose, and start and 
stop dates of administration.  All subjects will be questioned about medications/treatments at 
each site visit . 
Medication/treatments taken [ADDRESS_280147] application will be documented as a prior medication/treatment.  
Medications/treatments taken after first study product application will be docum ented as 
concomitant medication/treatments.  
[ADDRESS_280148] DISCONTINUATION/WITHDRAWAL  
7.[ADDRESS_280149] Discontinuation/Withdrawal  
A subject may withdraw from the study at any time at their own request or may be withdrawn 
at any t ime at the discretion of the investigator or sponsor for safety, behavioral reasons, or the 
inability of the subject to comply with the protocol  required schedule of study visits or 
procedures.   
The following circumstances require discontinuation of study  product and/or premature subject 
withdrawal:  
• Protocol violation that may impact the subject’s safety  
• Withdrawal of informed consent  
• Subject lost to follow -up  
• Unblinding of the subject  
• Pregnancy  
If a subject is discontinued or prematurely withdraws from the study, the reason(s) for 
discontinuation or withdrawal and the associated date must be documented in the relevant 
section(s) of the CRF.  
7.[ADDRESS_280150] wishes 
to and/or should continue in the study.  
A subject will be considered lost to follow up if they repeatedly fail to return for scheduled 
visits and is unable to be contact[CONTACT_9298]. Before a subject is deemed lost to follow 
up, the investigator or designee must make every effort to rega in contact [CONTACT_1155] (where 
possible, [ADDRESS_280151]’s last known mailing 
address or local equivalent methods). These contact [CONTACT_1156]. If contact 
[CONTACT_1157],  the investigator should inquire about the reason for withdrawal, request 
that the subject return all products provided  and, if appropriate , request that the subject return 
for a final visit and follow -up with the subject regarding any unresolved adverse e vents (AEs).  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280152] returns to the study site, at the 
investigator’s discretion, which could include an oral examination.  
Should the subject continue to be unreachable, they will be considered to have w ithdrawn from 
the study and lost to follow up.  
Lack of completion of all or any of the early termination procedures will not be viewed as 
protocol deviations so long as the subject’s safety was preserved.  
If the subject withdraws from the study and withdr aws consent for disclosure of future 
information, no further evaluations should be performed, and no additional data should be 
collected.  The sponsor may retain and continue to use any data collected before such 
withdrawal of consent.  
[ADDRESS_280153].  
8.1 Visit 1/Screening  
Screening procedures will be conducted by [CONTACT_737], or suitably qualified designee.  
Subjects will be screened within 7-21 days prior to randomization to confirm they meet the 
selection criteria for the study.  
The foll owing screening procedures will be completed, in the following order (wherever 
possible), and the findings recorded in the CRF:  
 
1. Informed Consent . 
2. Demographics . 
3. Review of medical history (including smoking/tobacco use status) and prior/concomitant 
medicati on/treatment . 
4. Screening assessment of oral malodor . 
5. OST and OHT examinations . 
6. Gingivitis (bleeding on probing) assessment . 
7. Review of the inclusion/exclusion criteria . 
8. Subject eligibility . 
9. Dispense washout products toothbrush  and diary. Instruct subjects in  diary completion.  
10. AEs recorded . 
8.1.1  Screening Procedures  
[IP_ADDRESS]  Informed Consent  
The investigator, or designee, must obtain informed consent from each subject participating in 
this study after adequate explanation of the aims, methods, objectives, and potential hazards of 
the study. An ingredients listing for the study dentifrices will  be provided to each subject during 
the consent process to enable them to confirm  they are not aware of any allergy or Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 33 of 62 
hypersensitivity to any of the ingredients listed.   Two copi[INVESTIGATOR_1076] (ICF) 
will be signed and dated by [CONTACT_423] , the subject will retain one copy and the other will be 
kept at site.  
The investigator, or designee, must also explain to the subjects that they are completely free to 
refuse to enter the study or to withdraw from it at any time.  Appropriate forms for do cumenting 
a signed and dated consent will be provided by [CONTACT_1158] . 
The investigator, or designee, should sign and date each copy of the ICF to confirm that the 
consent process was completed correctly after the subject has signed.   
The time the subject signed the ICF will be captured as this is the point from  which all AEs will 
be capture d. The date and time of consent will be recorded  in the CRF.  
If, during a subject’s participation in the study, any new information becomes available that 
may affect the subject’s willingness to participate in the study, each ongoing subje ct should 
receive a copy of this new information and be re -consented into the study. Each subject should 
be provided with a copy of the signed and dated amended consent form. The date of re -consent 
will be recorded on the CRF.  
After signing the ICF, subjec ts will undergo the screening assessments to confirm that they 
meet all the inclusion criteria and none of the exclusion criteria. If the subject is confirmed 
eligible by [CONTACT_093] (or designee) to participate in the study the subject is considered 
enrolled in the study.  
[IP_ADDRESS]  Demographics  
The following demographic information will be recorded in the CRF: year of birth, gender and 
race.  Ethnicity and race of subjects will be recorded in accordance with FDA Guidance  (US 
FDA, 2005 ). 
[IP_ADDRESS]  Medical History and Prior Medication/Treatment  
Details of relevant medical and surgical history (in the last year), including allergies or drug 
sensit ivity, will be documented in the CRF.  
Prior medications/treatments, including prescription and non -prescription drugs, dietary 
supplements and herbal remedies, taken in the last 28 days and prior to signing the informed 
consent form, will be documented in the CRF.  
[IP_ADDRESS]  Screening Assessment of Gingivitis (Bleeding  on Probing)  
To assess the inclusion requirement for gingivitis, the examiner should evaluate the number of 
bleeding sites elicited on probing as a measure of gingival  condition. The gingivae will be air  
dried and then the examiner will use an Oulix color coded  periodontal PCPII 5B Hu -Freidy or 
blunt -ended CPI [INVESTIGATOR_232157]. The probe will  be gently inserted into the gingival 
crevice to a depth of approximately 1 millimeter (mm) and  then run ar ound the tooth (at angle 
of ~ 60º to the long axis of the tooth), gently stretching the  epi[INVESTIGATOR_232158].  Minimum force should be used to 
avoid damage to the gingival tissue. The bleeding  will be assessed  on the facial and lingual 
gingival surfaces of each tooth. Three  sites for each tooth should be evaluated buccally/labially 
(distal, body, mesial  sites) and three sites lingually/palatally.  The percentage of bleeding sites 
shall be recorded in the CRF.  
 Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 34 of 62 
[IP_ADDRESS]  Screening Assessment of Oral Malodor  
At screening, subjects having abstained from oral hygiene procedures and food consumption 
for at least [ADDRESS_280154] 2 samples of mouth air taken by [CONTACT_232184] 9.2.1 .   
Subjects with insufficient mean hydrogen sulfide concentration in their mouth air per the 
inclusion criteria will be discontinued from the study.  
[IP_ADDRESS]  Oral Examinations  
Following r eview of the oral care products the subject is currently using (subject -reported 
product  names) to confirm they do not contain any  ingredients that could interfere with study 
outcom es, the clinical examiner(s) will perform the following examinations/assessments.  
• OST examination.  
• OHT examination.  
Oral examinations/assessments should only be performed by [CONTACT_1159](s) as 
described in Section 5.[ADDRESS_280155] flow, clinical assessments may be recorded on a paper source document 
and later transcribed into the CRF.   
[IP_ADDRESS]  Inclusion/Exclusion Criteria  
Inclusion and exclusion criteria information will be documented in th e CRF.  
[IP_ADDRESS]  Subject Eligibility  
The investigator and/or medically qualified designee will review the inclusion/exclusion 
criteria, medical history, prior and current medications /treatments and the findings of the oral 
examinations  to confirm subject eligibility  to participate in the clinical trial. This will be 
documented in the CRF.  
Eligible subjects will be appointed to attend the study site for baseline assessments (Visit 2) a 
minimum of 7 days, and a maximum of 21 days, after their screening visit and will be instructed 
to use only their supplied oral care products [washout product s] (according to their normal 
habit) until their next appointment.  
To prepare for study participation, subjects will be instructed in the Lifestyle Guidelines  and 
any Concomitant Medication/Treatment(s)  requirements of the protocol.  
8.2 Study Period  
8.2.1  Visit 2/Day 0 - Baseline  
Procedures will be conducted by [CONTACT_737], or suitably qualified designee.  
Subjects will undergo, in the following order (wherever possible) . 
 
1. Subject returns washout dentifrice and toothbrush.  
2. Changes in concomitant medication or non -drug treatments/procedures will be 
documented.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 35 of 62 
3. Spontaneous reporting of adverse events and those elicited by [CONTACT_1160] a non -leading question suc h as “How do you feel?” will be assessed.  
4. Pre-brushing assessment of oral malodor (organoleptic assessment directly from subject’s 
breath and VSC determination via OralChroma analysis of [ADDRESS_280156] breath 
obtained through a syringe).  
5. Review of th e inclusion/exclusion criteria.  
6. Subject eligibility assessed.  Subjects who do not meet the criteria for participation will be 
discontinued.  
7. Qualifying subjects will be stratified and randomized to treatment groups.  
8. Study products will be dispensed, includ ing sundry items.   
9. Instruct subject in product usage requirements/diary completion and demonstrate 
dispensing ribbon of dentifrice on to toothbrush head; supervise first brushing and first 
diary entry.  
10. 1 hour  (±5 minutes)  post brushing perform the post -brushing assessment of oral malodor 
(organoleptic assessment directly from subject’s breath and VSC determination via 
OralChroma analysis of [ADDRESS_280157] breath obtained through a syringe).  
11. Subject undergoes an OST examination.  
12. AEs and incidents reco rded.  
Randomized subjects will be appointed to attend the study site for their Week [ADDRESS_280158] flow, clinic al and instrumental assessments may be recorded on a paper 
source document and later transcribed into the CRF.   
 
8.2.2  Visit 3/Week 3 (Day 21 +2)  
Procedures will be conducted by [CONTACT_737], or suitably qualified designee.  
Subjects will undergo, in the following order (wherever possible) . 
 
1. Changes in concomitant medication or non -drug treatments/procedures will be 
documented.  
2. Spontaneous reporting of adverse events and those elicited by [CONTACT_1160] a non -leading question such as “How d o you feel?” will be assessed.  
3. Subject ’s study products and diary will be visual inspected to evaluate product compliance  
and adherence to protocol .  Subject continuance in the study confirmed.  
4. Pre-brushing assessment of oral malodor (organoleptic assessme nt directly from subject’s 
breath and VSC determination via OralChroma analysis of [ADDRESS_280159] breath 
obtained through a syringe).  
5. Supervise d tooth brushing  with study product . 
6. Return of study products.  
7. 1 hour (±5 minutes) post brushing perform the post -brushing assessment of oral malodor 
(organoleptic assessment directly from subject’s breath and VSC determination via 
OralChroma analysis of [ADDRESS_280160] breath obtained through a syringe).  
8. Subject undergoes an OST and OHT examination.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280161] flow, clinical and instrumental assessments may be recorded on a paper 
source document and later transcribed into the CRF.  
8.2.3  Study Procedures  
[IP_ADDRESS]  Diary Review  
The diary should be reviewed at every visit by [CONTACT_093], or suitably qualified designee, 
and the subject. Any subject comment captured in the diary which is considered an adverse 
event will be assessed and reported as defined in the  Adverse Event and Se rious Adverse Events  
section of this protocol.  
Any additional comments  relating to medications/treatments provided in the diary will be 
reviewed by [CONTACT_1161].  
Additional and missed product applications will be considered deviations from the protocol and 
will be recorded on the Deviations Log  and as a deviation in the CRF . 
[IP_ADDRESS]  Study Conclusion  
The Study Conclusion page of the CRF will be completed for all subjects w hether they 
completed all study procedures or if they were discontinued from the study early.  If the subject 
was discontinued early, at any point during the study, the primary reason for withdrawal should 
be recorded on the Study Conclusion page.  
If a sub ject has any clinically significant, study -related abnormalities or AEs at the end of the 
study, the sponsor’s  medical monitor (or designated representative) should be notified, and the 
subject may be asked to remain at the clinical site or be asked to ret urn for a follow -up visit to 
ensure any issue is resolved or deemed not clinically significant.  
[IP_ADDRESS]  Follow -up Visit / Phone Call  
The study site may contact a subject to follow up an AE post -study completion/withdrawal and, 
in some circumstances, request they return to the site for additional follow -up visits (final safety 
assessments). If needed, additional clinical examinations may  be carried out at such visits.  
[ADDRESS_280162].  When a protocol required assessment cannot be performed, the investigato r (or 
designee) will document the reason for the missed assessment as a protocol deviation and any 
corrective and preventative actions that they have  taken to ensure the required processes are 
adhered to as soon as possible.  The sponsor  must be informed o f any missed assessments in a 
timely manner.  The outcome of all examinations and assessments should be recorded in the 
CRF.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280163]’s suitability and 
eligibility for enrollment into the study.  
9.1.[ADDRESS_280164]’s suitability and 
eligibilit y for enrollment into the study.  
9.2 Efficacy Assessments  
The following efficacy assessments will be performed by  [CONTACT_1163] (s), at the times and in the order defined in the Study Procedures  section  of this 
protocol.  
If in the opi[INVESTIGATOR_1077] a subject is between defined grades/scores, a conservative 
approach should be used to provide the final score.  The same approach should be applied 
throughout the study to ensure consistency in the gradi ng of the scores at all timepoints.  
9.2.1  Mouth Air VSC Determination  
Mouth air VSC determination will be performed pre - and 1 hour (±5 minutes) post-brushing at 
Visits 2&3.  
The mouth air sample will be evaluated using the OralChroma Halitosis Measuring instrume nt 
(Model CHM -2 [Nissha FIS, Inc.; Osaka, Japan]) in agreement with the manufacturer’s 
instructions.  The OralChroma is a portable gas chromatograph with a highly sensitive 
semiconductor gas detector which can determine the concentration of the three main VSCs in 
breath (hydrogen sulfide, methane thiol and dimethyl sulfide).  
In line with recommendations, the OralChroma instrument will have been calibrated by [CONTACT_232185] (Tangerman and Winkel, 2008 ).  If more than 
one OralChroma device is used in this study, the same subject will be evaluated by [CONTACT_232186] e for every assessment at all visits.  The concentration values (in parts per billion [ppb]) 
of hydrogen sulfide, methanethiol and dimethyl sulfide will be recorded in the CRF separately, 
and the total VSC concentration will be calculated as the sum of the  [ADDRESS_280165]’s mouth until the lips reach the stopper 
(flange).  Subjects will be instru cted to seal their lips tightly around the syringe holding the 
syringe gently between their front teeth without touching the tip with the tongue or allowing 
saliva to enter the syringe.  Subjects should hold this position for 30 seconds while breathing 
through their nose.  The trained OralChroma technician will slowly pull the syringe pi[INVESTIGATOR_55274] 
(plunger) away from the mouth / to the end of the syringe and then push the pi[INVESTIGATOR_232159] / returning the gas into the mouth; the technician will repeat t his pull -out and pull -in 
process  and the mouth air will sample be collected on the third pull -out.  Should the sample not Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 38 of 62 
be taken correctly (e.g. subject does not correctly seal their lips around the syringe) a further 
sample may be taken.  
This process wi ll be repeated so that two syringes full of mouth air will be collected for each 
subject at each time period and the average of the two readings of total VSCs, and the three 
gases will be captured for each measurement time period (Screening, Baseline and a ll post -
product use assessments).  
After the syringe is removed from the mouth, the trained technician  will wipe the syringe tip 
with clean, dry tissue paper to remove saliva. The syringe will not be wiped with alcohol or an 
antiseptic solution or touched w ith a bare or gloved hand that has been exposed to an antiseptic 
solution. After wipi[INVESTIGATOR_007], the technician will adjust the volume of gas in the syringe to 1.[ADDRESS_280166], which will serve as a source document, and the data from the 
OralC hroma printout of the two mouth samplings at each measurement timepoint will be 
recorded in the CRF.  
9.2.2  Organoleptic Assessment of Oral Malodor  
At each oral odor evaluation (pre - and 1 hour (±5 minutes) post-brushing at Visits 2 and 3), the 
subjects will atte nd an odor grading station.  T hey will place one end of a clean and sterile 
cylinder, about 1 3/4 inches long by 1 1/[ADDRESS_280167] from the palate of their mouth.  
Oral odor will be graded using  the following scale  (Rosenberg et al. , 1991b ): 
 
0 = No appreciable odor  
1 = Barely noticeable odor  
2 = Slight but clearly noticeable odor  
3 = Moderate odor  
4 = Strong odor  
5 = Extremely foul odor  
 
The organoleptic assessors (using a panel of at least 3 assessors) will be blinded to the subject’s 
product allocation and will have a minimum of a two -minute interval  between individual 
assessments to allow adequate recovery of the assessors ’ olfactory senses.  Wherever possible 
the same assessors will be used throughout  the study to aid consistency of evaluation, however 
assessors may be replaced with another calibrated judge(s) in the event of illness or availability 
issues.  
Prior to undergoing this assessment, subjects will be trained in the appropriate technique to 
ensure familiarity with the procedure requirements.  
Prior to this study, the organoleptic assessors will have been recently (within the past year) 
calibrated and standardized with a Kappa statistic >0.6 in accordance with the American Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 39 of 62 
Dentistry Association g uidelines for the testing of Products Used in the Management of Oral 
Malodor (ADA, 2016 ). 
9.3 Safety and Other Assessments  
The following safety assessments will be performed by  [CONTACT_1163] (s), at the times and in the order defined in the Study Procedures  section of this 
protocol.  Additionally, to help prevent COVID -19 transmission within the study, the 
measurement of the temperature of subjects and/or questioning and/or Covid testing (PCR or 
lateral flow) of the subjects may be utilized at any site visit at the examiner’s discretion  and per 
the clinical site’s procedures . 
9.3.1  Oral Soft Tissue  (OST)  Examination  
This procedu re will be conducted by a qualified, experienced clinical  examiner.  The OST 
examination will be accomplished by [CONTACT_1169] , as 
appropriate. The examination will cover  the oral labial mucosa (including lips), bucc al mucosa, 
mucogingival folds, gingival mucosa, hard palate, soft palate, tonsillar area, pharyngeal area, 
tongue, sublingual area, submandibular area and salivary glands.   Findings from  the 
examination will be recorded in the CRF as either normal or abnor mal, with details of any 
abnormalities. The results of the OST examination performed at screening will be used to 
determine subject eligibility. Any new OST abnormality or worsening of a pre -existing 
condition observed by [CONTACT_232187].  
Where possible, this procedure should be conducted by a single clinical examiner.   
9.3.[ADDRESS_280168] Tissue (OHT) Examination  
This procedure should be conducted by a qualified, experienced clinical  examiner.  The OHT 
examination will be accomplished by [CONTACT_1171], using retraction aids as appropriate 
and will identify any grossly carious lesions , signs of erosive wear, enamel irregularities, tooth 
fracture, gross generalized dental c aries decay, decalcification and faulty restorations. The 
presence of any implants, fixed or removable dentures, fixed or removable orthodontic 
braces/bands, fixed orthodontic retainers, full crowns or veneers will be recorded. Observations 
will be listed as either absent or present, and conditions noted as present will be described in 
the CRF. Any change observed by [CONTACT_1172] . 
The results of the  OHT examination  performed at Screening will be used to determine subject 
eligibility.  
Where possible, this procedure should be conducted by a single clinical examiner.  
9.3.3  Pregnancy Testing  
Urine pregnancy testing of subjects of child -bearing potential is not required for t his study ( see 
Section 4.2  for details ).  Subjects of child -bearing potential will be asked  to provide verbal 
confirmation of pregnancy status at screening (Visit 1) and to inform site staff if they find they 
are pregnant while participating in the study.  In case of a positive confirmed pregnancy, the 
subject will be withdrawn from the study.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280169] or study.  
10.1 Definition of an Adverse Event (AE)  
An AE is any untoward medical occurrence in a clinical study subject, temporally associated 
with the use of a study product including any washout or lead -in product (or medical device), 
whether or not considered related to the study product, including any washout or lead -in product 
(or medical device).  
NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the 
use of a study product including any washout or lead -in product (or medical device).  
Events Meeting  the AE Definition:   
• Any abnormal laboratory test results (hemato logy, clinical chemistry, or urinalysis) or 
other safety assessments (e.g. ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinically significant in the 
medical and scientific judgment of the investi gator (i.e., not related to progression of 
underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study p roduct administration even though 
it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
product or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae.  
• "Lack of efficacy" or "failu re of expected pharmacological action" per se will not be 
reported as an AE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of 
efficacy will be reported as AE if they fulfill the definition of an AE.  
Events NOT  meeting the AE definition:  
• Any clinically significant abnormal laboratory findings (if applicable) or other abnormal 
safety assessments which are associated with the underlying disease, unless judged by 
[CONTACT_232188]’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the subject’s 
condition.  
• Medical or surgical procedure (e.g. endoscopy, appendectomy) is not the AE. The 
condition that leads to the procedure is an AE (e.g. appendicitis).  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 41 of 62 
• Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_17399] l). 
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
10.2 Definition of a Serious Adverse Event (SAE)  
A Serious Adverse Event (SAE) is a particular category of an a dverse event where the adverse 
outcome is serious. If an event is not an AE per definition above, then it cannot be an SAE even 
if serious conditions are met (e.g. hospi[INVESTIGATOR_1080]/symptoms of the disease under study, 
death due to progression of d isease).  
A serious adverse event is any untoward medical occurrence at any dose that:  
• Results in death  
• Is life -threatening   
▪ The term 'life -threatening' in the definition of 'serious' refers to an event in which 
the subject was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe;  
• Requires inpatient hospi[INVESTIGATOR_1081]   
▪ In general, hospi[INVESTIGATOR_5184] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_1083]/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospi[INVESTIGATOR_232160]. If a complication prolongs hospi[INVESTIGATOR_1085], the event is serious. When in doubt as to whether 
“hospi[INVESTIGATOR_059]” occurred, or was necessary, the AE should be considered 
serious.  
▪ Hospi[INVESTIGATOR_17048] a pre -existing condition that did not 
worsen from baseline is not considered an AE.  
• Results in persistent or significant disability/incapacity  
▪ The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
▪ This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g. sprained ankle) which may interfere with or 
preven t everyday life functions but do not constitute a substantial disruption  
• Results in congenital anomaly/birth defect  
• Other situations:  
▪ Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations su ch as important medical events that 
may not be immediately life -threatening or result in death or hospi[INVESTIGATOR_232161]. These events 
should usually be considered serious.  
▪ Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 42 of 62 
dyscrasias or convulsions that do not result in hos pi[INVESTIGATOR_059], or development of 
drug dependency or drug abuse.  
Note:  Classification of an AE as ‘serious’ is based on the outcome of the event and is a factor 
in determining reporting requirements.  
10.[ADDRESS_280170] provides consent 
to participate in the study by [CONTACT_1174] (signature) of the ICF and until [ADDRESS_280171] (or last procedure ).  
Medical occurrences that began before obtaining informed consent will be recorded in the 
Medical History/Current Medical Conditions  section of the CRF not the AE section.  
Details recorded by [CONTACT_1175] a diary or similar document that meet the defi nition of an AE 
must also be discussed with the subjects and transcribed in the AE section of the CRF.  
All SAEs will be recorded and reported to the sponsor or designee immediately and under no 
circumstance should this exceed [ADDRESS_280172](s), participation in the study, or  a study 
procedure, or that caused the subject to discontinue the study product or study.  
Spontaneous reporting of adverse events and those elicited by [CONTACT_1176]-leading such as “How do you feel” will be assessed and any AE’s recor ded in the CRF and 
reported appropriately.  
The investigator (or medically qualified designee) is to report all directly observed AEs and all 
AEs spontaneously reported by [CONTACT_1177]. In addition, each study subject will be 
questioned about AEs.  
Each AE is to be assessed to determine if it meets the criteria for a SAE.  If an SAE occurs, 
expedited reporting will follow local and international regulations, as appropriate.  
When an AE occurs, it is the responsibility of the investigator (or medically qu alified designee) 
to review all documentation (e.g. hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
related to the event.  
The investigator or site staff will then record all relevant information regarding an AE in the 
CRF and all details rela ting to an SAE in the paper SAE Form provided.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 43 of 62 
It is not acceptable for the investigator (or medically qualified designee) to send photocopi[INVESTIGATOR_1089]’s medical records to the sponsor  in lieu  of completion of the AE CRF page/SAE 
form.  
There may be instances when copi[INVESTIGATOR_1090] .  In this instance, all subject identifiers, except for the subject number, will be redacted 
on the copi[INVESTIGATOR_1091] . 
The investigator (or medically qualified designee) will attempt to establish a diagnosis of the 
event based on signs, symptoms, and/or other clinical information.  The diagnosis will be the 
documented as the AE/SAE where known and not the indivi dual signs/symptoms. (e.g. upper 
respi[INVESTIGATOR_1092], seasonal allergy, etc. instead of runny nose).  
AEs elicited by [CONTACT_093] (or medically qualified designee) in a standard manner at the 
study visits should also be recorded in the AE secti on of the CRF and/or using the SAE form 
(subject to the classification of the AE). Care will be taken not to introduce bias when 
questioning a subject about any changes in their health. Open -ended and non -leading verbal 
questioning should be used.  
10.4.[ADDRESS_280173] copi[INVESTIGATOR_1093] ‘paper’ SAE form will be provided in the 
investigator study master file. Original SAE for ms will be retained in the investigator study 
master file.  
It is essential to enter the following information:  
• Protocol and subject identifiers  
• Subject demography  
• Description of events, with diagnosis if available  
• Investigator opi[INVESTIGATOR_232162] s tudy product (or study procedure, if 
appropriate)  
• Criterion for seriousness.  
The following are desirable and are of particular relevance for investigator and the sponsor  
assessment of the SAE report:  
• Date of onset of AE  
• Date AE stopped, if relevant  
• Study product start date  
• Study product end date if relevant  
• Action taken in relation to the study product  
• Outcome if known  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280174] be scanned and e -mailed to the Case 
Management Group mailbox (  ), with copy to the 
appropriate  CH Study Manager, with the study number and subject number in the subject line 
of the email immediately and under no circumstance should this exceed 24 hours  after study 
site personnel learn of the event. The investigator will submit any updated SAE data to the 
sponsor, immediately and  under no circumstance should this exceed 24 hours of it being 
available.  
The initial report will be followed up with more inf ormation as relevant, or as requested by [CONTACT_1178].  
The CH Study Manager will be responsible for forwarding the SAE form to other CH personnel 
as appropriate.  
10.5 Evaluating Adverse Events  
10.5.1  Assessment of Intensity  
The investigator or medically qualified designee will make an assessment of intensity for each 
AE reported during the study and will assign it to one of the following categories:  
• Mild:  An event that is easily tolerated by [CONTACT_423], causing minimal discomfort and 
not interfering wit h everyday activities.  
• Moderate:  An event that is sufficiently discomforting to interfere with normal everyday 
activities  
• Severe:  An event that prevents normal everyday activities.  
NOTE: An AE that is assessed as severe should not be confused with an SA E. Severe is a 
category utilized for rating the intensity of an event; and both non -serious AEs and SAEs can 
be assessed as severe. For example, a headache may be severe (interferes significantly with the 
subject's usual function) but would not be classifi ed as serious unless it met one of the criteria 
for SAEs, listed above. An event is defined as ‘serious’ when it meets at least 1 of the predefined 
outcomes as described in the definition of an SAE, NOT when it is rated as severe.  
10.5.2  Assessment of Causality  
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
For each AE (serious and non -serious), the investigator (or medically qualified designee) must  
provide an assessment of causality on the AE CRF page an d the SAE form (subject to the 
classification of the AE). The investigator will also document in the medical notes that they 
have reviewed the AE and assessed causality, where applicable.  
A “reasonable possibility” of a relationship conveys that there are  facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. 
Generally, the facts (evidence) or arguments to suggest a causal relationship should be provided.  
The investigator will use clinical judgme nt to determine the relationship and will also consult 
the Safety Statement, in the determination of their assessment.  Alternative causes, such as 
underlying disease(s), concomitant therapy, other risk factors, and the temporal relationship of 
the event t o the study product will be considered and investigated.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_003]
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 45 of 62 
For each AE/SAE, the investigator must document in the medical notes that they have reviewed 
the AE/SAE and has provided an assessment of causality.  
The investigator’s assessment of causality must be  provided for all AEs (serious and non -
serious); the investigator must record the causal relationship in the CRF, as appropriate, and 
report such an assessment in accordance with the SAE reporting requirements if applicable.  
There may be situations when an  SAE has occurred, and the investigator has minimal 
information to include in the initial report to the sponsor .  However, it is very important that 
the investigator always make an assessment of causality for every event prior to the initial 
transmission o f the SAE data to the sponsor . The investigator may change their opi[INVESTIGATOR_1095] -up information and send an SAE follow -up report with the updated 
causality assessment.  
10.6 Follow -up of AEs and SAEs  
After the initial AE/SAE report, the  investigator is required to proactively follow up with each 
subject and provide further information on the subject’s condition.  
All AEs (serious and non -serious) will be followed until resolution, until the condition 
stabilizes, until the event is otherwi se explained, or until the subject is lost to follow -up.   
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may be indicated or as requested by [CONTACT_232189]/or causality of the AE. This may include additional laboratory 
tests or investigations, histopathological examinations, or consultation with other health care 
professionals.  
New or updated information will be recorded on the AE CRF page and on the SAE form (subject 
to the classification of the AE).  
The investigator will submit any updated SAE data to the sponsor  within [ADDRESS_280175] or study 
participation, the investigator will promptly notify the sponsor  by [CONTACT_1180] (  ), with copy 
to the appropriate CH Study Manager.  
The investigator will submit any updated SAE data to the sponsor  within the designated 
reporting time frames.  
10.[ADDRESS_280176] under clinical investigation.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_003]
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 46 of 62 
Prompt notification of SAEs by [CONTACT_1181].  
The sponsor  will comply with country specific regulatory requirements relating to safety 
reporting to the regulatory authority, IRB/EC and investigators.  
Both th e investigator and the sponsor will comply with all local medical device reporting 
requirements  
Investigator safety reports must be prepared for suspected unexpected serious adverse reactions 
(S[LOCATION_003]R) according to local regulatory requirements and sponsor policy and forwarded to 
investigators as necessary.  
An investigator who receives an investigator safety report describing a SAE or other specific 
safety information e.g. summary or listing of SAE from the sponsor will review and then file it 
along with the  Safety Statement  in the investigator study master file, and will notify the 
IRB/IEC, if appropriate according to local requirements.  
10.[ADDRESS_280177] pregnancy information on the appropr iate form scan and e -mail it 
to the Case Management Group mailbox (  ), with copy 
to the appropriate CH Study Manager. Original pregnancy information forms will be retained 
in the investigator study master file.  
The subject will be followed to determine the outcome of the pregnancy. Information on the 
status of the mother and infant / neonate (including concomitant medications taken by [CONTACT_1182]) will be forwarded by [CONTACT_232190] (  ), with cop y to the appropriate CH 
Study Manager. Generally, follow -up will be no longer than 6 to 8 weeks following the 
estimated delivery date. Any termination of the pregnancy will be reported.  
While pregnancy itself is not considered to be an AE, abnormal pregnan cy outcomes (e.g. 
spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are, and 
should be recorded as an SAE.  
Any female subject who becomes pregnant while participating will be withdrawn from the 
study.  
10.10  Medical Device In cidents  
Both the investigator and the sponsor will comply with all local medical device reporting 
requirements.  
Medical devices are being provided by [CONTACT_1184]; the medical device in 
this study is the supplied toothbrush.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_003]
[COMPANY_003]
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 47 of 62 
10.10.1  Definitio n of an Incident  
A medical device incident is any malfunction or deterioration in the characteristics and/or 
performance of a device as well as any inadequacy in the labeling or the instructions for use 
which, directly or indirectly, might lead to or might  have led to the death of a subject/user/other 
person or to a serious deterioration in their state of health.  
Not all incidents lead to death or serious deterioration in health. The nonoccurrence of such a 
result might have been due to other fortunate circ umstances or to the intervention of health care 
personnel.  
It is sufficient that:  
An incident  associated with a device happened and  
• The incident  was such that, if it occurred again, might lead to death or a serious 
deterioration in health.  
• A serious deteri oration in state of health can include any of the following:  
• Life-threatening illness  
• Permanent impairment of body function or permanent damage to body structure  
• Condition necessitating medical or surgical intervention to prevent one of the above  
• Fetal distress, fetal death, or any congenital abnormality or birth defects  
Examples of incidents:  
• A subject, user, caregiver, or healthcare professional is injured as a result of a medical 
device failure or its misuse.  
• A subject’s study treatment is interrupted  or compromised by a medical device 
failure.  
• A misdiagnosis due to medical device failure leads to inappropriate treatment.  
• A subject’s health deteriorates due to medical device failure.  
10.[ADDRESS_280178]'s 
medical records, if in accordance with the investigator's normal clinical practice, and on the 
appropriate Incident Report Form.  In addition, for incidents fulfilling the definition of an AE 
(serious and non -serious), the appropriate AE CRF page and SAE form will be compl eted and 
reported as per the AE and SAE reporting sections.  
The Incident Report Form will be completed as thoroughly as possible and signed by [CONTACT_1185] .  It is very important that the investigator describes 
any cor rective or remedial actions taken to prevent recurrence of the incident.  
The completed Incident Report Form should be scanned and emailed to the Case Management 
Group mailbox (  ), with copy  to the appropriate  CH 
Study Manager,  with the study number and subject number in the subject line of the email 
immediately and under no circumstance should this exceed [ADDRESS_280179] eted SAE form should be sent together 
with this report form.  However, if a copy of the SAE report is sent with this form, this does not Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_003]
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280180] the procedure to report an SAE.  The original Incident Report Form will be retained in 
the investigator study m aster file.  
The initial report will be followed up with more information as relevant, or as requested by [CONTACT_1178].  
The investigator will follow the following directions regarding the reporting of a device failure 
(malfunction):  
• Notify the spon sor immediately (by [CONTACT_1186]).  
• Schedule the subject to return to the site promptly to return the failed device.  
• Record any incidents on the CRF and Incident Report Form following instructions given 
in the section above.  
• For any  incident/malfunction occurring with a medical device (including those that are 
part of combination products) supplied by [CONTACT_456] , return the failed device to the 
sponsor as soon as possible, including documentation of the details of the failure.  
• For a ny incident/malfunction occurring with a medical device (including those that are 
part of combination products) supplied by [CONTACT_1187], report the incident to the 
device manufacturer and follow the manufacturer instructions for the return of the  failed 
device (whilst keepi[INVESTIGATOR_1096]).  
10.[ADDRESS_280181] or are 
withdrawn from the study.  
The investigator is responsible for ensuring that follow -up includes any supplemental 
investigations as indicated to elucidate the nature and/or causality of the incident.  
New or updated information will be recorded on the originally completed Incident Report form 
with all changes signed and dated by [CONTACT_093].  
10.[ADDRESS_280182] udies.  
The investigator, or responsible person according to local requirements (e.g. the head of the 
medical institution), will comply with the applicable local regulatory requirements relating to 
the reporting of incidents to the IRB/IEC.  
[ADDRESS_280183] or both, depending on the data collection method.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280184] data will be entered into an electronic CRF (eCRF), using a validat ed 
system. Data relating to SAEs, pregnancy and incidents will also be collected on paper forms . 
The investigator is responsible for verifying that data entries are accurate and correct by 
[CONTACT_1189].  
The source documents (e.g. hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, 
memoranda, subject diaries, questionnaires, evaluation checklists, pharmacy dispensing 
records, recorded data from automated instruments, microfiches, photographic negatives, 
microfilm o r magnetic media, x -rays, subject files and records kept at the pharmacy, at the 
laboratory and at the medico -technical departments involved in the clinical study) which 
contain the source of data recorded in the CRF should be specified.  The CRF and or di ary can 
be used as a source document at the discretion of data management.  
Each subject will be assigned and identified by a unique Screening Subject Number. Any 
reference made to an individual subject within the study must be done using their unique 
Screening Subject Number.  
11.[ADDRESS_280185] who has given informed consent/assent the CRF must be completed and signed 
by [CONTACT_079] (or authorized designee) to certify that the data are complete and 
correct.  The investigator must maintain accurate documentation (source data) that supports the 
information entered in the  CRF.  
Management of clinical data will be performed in accordance with Third Party Vendor 
applicable standards and data cleaning procedures with oversight by [CONTACT_232191], for example, to correct  errors and inconsistencies in  the data.  
To protect the privacy of subjects, no Personal Information (PI) (including the subject's name 
[CONTACT_1218]) is to be recorded in the CRF or as part of the query text.  
All CRF pages should be completed during a subject assessm ent when the CRF has been 
designated as the source.  Data that is sourced elsewhere should be entered into the CRF in an 
agreed upon timeframe between the Investigator and sponsor . 
The sponsor  will obtain and retain all CRFs and associated study data as ap plicable at the 
completion of the study.  
11.2 Data Handling  
Documentation of all data management activities should allow step -by-step retrospective 
assessment of data quality and study performance.  
Any changes or corrections to data will be performed in the E lectronic Data Capture (EDC) 
System, and it will include rationale for changes. The EDC system has an audit trail, which will 
provide a complete record of the changes and corrections endorsed by [CONTACT_737].  
Adverse events will be coded using Medical Dictionary for Regulatory Activities (MedDRA) 
and any concomitant medications terms (if applicable) using a validated medication dictionary, 
WHODrug . Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 50 of 62 
11.2.1  Data Queries  
Programmed edit checks will be generated automatically, as the data are being entered into th e 
system. Reports and listings on the CRF data will also be run, in addition to the queries already 
programmed and generated by [CONTACT_1190], to raise manual queries as needed for site 
clarification or correction. The sponsor’s third party vendor  will raise queries as needed on 
safety data to code the terms (AEs and Drugs or concomitant medication) appropriately.  
The study monitor will perform ongoing review of the CRFs in accordance with the monitoring 
plan, to confirm that data entered into the CRF by [CONTACT_232192], 
complete, and verifiable from source documents; that the safety and rights of participants are 
being protected; and that the study is being conducted in accordance with the currently approved 
protocol and any other study  agreements, ICH GCP, and all applicable regulatory requirements.  
Any queries will be generated in the EDC System to the Investigator or designee, enabling the 
errors to be addressed in parallel with Data Management review. The study monitor can also 
run r eports and listings on the CRFs, to raise manual queries as needed for site clarification or 
correction.  
11.3 Processing Patient Reported Outcomes  
Paper based patient reported outcome (PRO) data may be recorded to  a diary, questionnaire, or 
other specified document, etc. and entered into the data management system (DMS).    
All PRO source data should be reviewed by [CONTACT_232193] m onitor to ensure 
accurate transcription of data and that any potential A Es or concomitant medications reported 
on these documents are discussed with the subject and transcribed accurately to the CRF and/or 
DMS.   PROs that are classed as source data will be retained by [CONTACT_232194]/certified 
copi[INVESTIGATOR_65349] a  designated vendor or sponsor  as required.   
To protect the privacy of subjects, no Personal Information (PI) (including the subject's name 
[CONTACT_65409]) is to be recorded on any PRO that will be forwarded to the sponsor  or 
Third -Party Vendor.  
[ADDRESS_280186] 
100 complete the study (at least 50 subjects per treatment arm). It is considered sufficien t to 
have 100 subjects complete in this study to meet the study’s objectives. The subjects will be 
stratified by [CONTACT_232195].  
Existing [COMPANY_004]CH studies were referred to for information and data to enable calculation of an 
appropriate pow er and sample size however no relevant information was observed for a 3 -week 
study in a gingivitis population as planned for this study.  
Data from a published study that evaluated halitosis in subjects with gingivitis and periodontitis  
(Pham et  al., 2011 ) was taken into consideration to provide information regarding the variability 
and sample size for this endpoint. The sample size in this literature was N=116 for the gingivitis 
population and the variability estimate was observed to be 0.46 for the organo leptic score. The 
scoring was on a 5 -point scale with very similar descriptors to those to be used in this  study 
however only one assessor was used for organoleptic score assessment (as opposed to 3 Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 51 of 62 
assessors which will be used in this study). Considering the number of assessors in this study, 
the standard deviation was estimated to be 0.265 (0.46/sqrt(3)).  
Using the standard deviation of 0.265, for 50 subjects per arm (100 subjects completing the 
study) the detectable mean difference is estimated to be 0.1 5 for 80% power and alpha=0.05.  
12.[ADDRESS_280187] received. All 
assessments of safety will be based on this analysis population.  
The modified Intent -To-Treat (mITT) population will include all randomized subjects who 
complete at least one use of study product and have at least one post treatment  efficacy 
assessment. This population will be based on the study product to which the subject was 
randomized. All assessments of efficacy will be primarily based on this analysis population.  
The per protocol (PP) population is defined as all subjects in the mITT population who have at 
least one assessment of efficacy considered unaffected by [CONTACT_1193].  
12.2.2  Exclusions of Data from Analysis   
Exclusion of any data from the analyses will be determined during a Blinded Data Review 
(BDR) Meeting prior to data base lock. Any reasons for exclusion from an analysis population 
will be listed, if applicable.  
A PP analysis will be performed on the primary  endpoint  if there is more than 10% difference 
in the number of subjects between the PP and mITT populations. A decision on whether a PP 
analysis will be performed will be made prior to study unblinding (release of the randomization 
codes ).  
12.3 Statistical Analyses  
This section is a summary of the planned statistical analyses focusing on  the primary and 
secondary endpoints  in detail with a brief overview for other endpoints . Additional details of 
all the proposed statistical analysis will be documented in the statistic al analysis plan ( SAP), 
which will be written following finalization of the protocol and prior to study unblinding.  
12.3.1  Primary Analysis  
The mean breath o rganoleptic score  at a visit / time point will be derived across all of the 
recorded organoleptic score s recorded at the visit / time point.  
The primary endpoint for the study is the change in mean breath o rganoleptic score  from 
Baseline (pre -brushing) to 3 weeks (pre -brushing) and the comparison between the 
Experimental and Reference Dentifrices in the mITT population. This will be assessed at the 
two-sided 5% significance level.  
An ANCOVA model will be used to analyze the change in mean breath organoleptic score from 
Baseline (pre -brushing) to 3 weeks (pre -brushing)  with study product and gender as fixed 
effects and the mean Baseline (pre -brushing)  breath organoleptic score  as a covariate. The least 
square means for each study product will be presented based on observed margins and used to 
test for < [ADDRESS_280188] squar e means for the Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280189] for a difference between products. The two -sided p -value s and 95% confidence intervals 
will be provided.  
The assumption of normality and homogeneity of variance in the ANCOVA  will be 
investigated. In case of violation of these assumptions, a suitable nonparametric test (adjusted 
for gender ) will be performed, and results will be provided to support the ANCOVA  results.  
The mean pre -brushing breath organoleptic score  values across the study and change from 
baseline will be summarised descriptively.   
12.3.2  Secondary Analys es 
All secondary endpoint analyses will be performed on the mITT population. There will be no 
adjustment for multiplicity in the analyses described in this section.   
Volatile Sulfur Compounds (VSC)  
There will be individual  evaluations of hydrogen sulfide, methanethiol and dimethyl sulfide 
concentration s in breath  taken at each visit (Baseline and Week 3) at each time point (pre -
brushing /[ADDRESS_280190] - brushing). The Total VSC at a visit/time point will have two samples. 
This will be derived as the sum of the hydrogen sulfide, methanethiol and dimethyl sulfide 
conce ntration s in breath  and then the mean over two samples to derive one value used for 
analysis per visit/timepoint. The sum and the average will be performed on the raw scale and 
final value will be transformed.  
For each concentration ( hydrogen sulfide, met hanethiol , dimethyl sulfide , Total VSC), the 
result will be log (base 10) transformed. Details of handling zero values will be detailed in the 
SAP.  
The ANCOVA models described below will be applied for each of the mean concentrations 
using a different def inition of Baseline and post -baseline as follows:  
• Baseline = Baseline (pre -brushing), Post -baseline = Week 3 (pre -brushing)  
• Baseline = Baseline (pre -brushing), Post -baseline = Week 3 ([ADDRESS_280191] -brushing)  
• Baseline = Baseline (pre -brushing), Post -baseline = Baseline ([ADDRESS_280192] -brushing)  
• Baseline = Week 3 (pre -brushing), Post -baseline = Week 3 ([ADDRESS_280193] -brushing)  
The appropriate change from Baseline in the logged value will be analyzed for each post -
baseline concentration using an ANCOVA model with stud y product and gender as fixed effects 
and the respective logged mean Baseline concentration  as a covariate . The least square means 
for each study product will be based on observed margins to test for < 0 change (on the logged 
scale)  from baseline. The diff erence between least square means for the Experimental Dentifrice 
compared to the Reference Dentifrice will be used to test for a difference between products. As 
well as presenting the least square means and differences on the log scale, the corresponding 
back transformed values (antilog base 10) will be presented to represent percent reduction from 
baseline and percent difference from control relative to baseline. The two -sided p -value s and 
95% confidence intervals  (logged and back -transformed) will be provided.  
The raw and logged  concentration (hydrogen sulfide, methanethiol, dimethyl sulfide, Total 
VSC)  values across the study and change s from baseline (for each type of baseline detailed 
above)  will also be summarised descriptively.   
 Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280194] -baseline  mean breath o rganoleptic score  definitions:  
• Baseline = Baseline (pre-brushing), Post -baseline = Week 3 ([ADDRESS_280195] -brushing)  
• Baseline = Baseline (pre -brushing), Post -baseline = Baseline ([ADDRESS_280196] -brushing)  
• Baseline = Week 3 (pre -brushing), Post -baseline = Week 3 ([ADDRESS_280197] -brushing)   
12.3.[ADDRESS_280198] received.  
Safety analyses will focus on:  
• Adverse Events (AEs)  
All AEs will be reviewed by [CONTACT_1194], or designee, prior to databa se lock 
and unblinding and will be coded using the MedDRA.  AEs will be categorized as oral and non -
oral by [CONTACT_232196] . AEs will be regarded as ‘treatment’ emergent if 
they occur on or after the first use of study product at the Ba seline visit.  
The following AEs summaries (number of distinct AEs and frequency/proportion of subjects 
affected will be presented by [CONTACT_1195] :  
▪ Treatment emergent AEs  
▪ Treatment emergent AEs by [CONTACT_1196] (SOC)  and Preferred Term (PT) ;  
▪ Treatment emergent AEs by [CONTACT_1197]/Non -Oral and PT;  
▪ Treatment emergent treatment related AEs by [CONTACT_1197]/Non -Oral and PT;  
▪ Treatment emergent treatment related serious AEs by  [CONTACT_1198];  
A listing of all AEs will be presented for all subjects in the Sa fety population. Separate listings 
will be presented for any deaths, serious AEs and AEs leading to study or product 
discontinuation.  
• Oral Soft Tissue and Examinations  
▪ Summary of abnormalities at each visit for each area examined  
• Oral Hard Tissue and Examinations  
▪ Will be listed only.  
• Exposure and compliance with study product  
▪ Detailed in section [IP_ADDRESS].  
12.3.4  Demographic and Baseline Characteristics  
Demographic  and randomized stratification data will be summarized descriptively.  
12.3.5  Study Drug/Product Complian ce and Use of Other Therapi[INVESTIGATOR_014]  
[IP_ADDRESS]  Study Drug/Product Compliance  
Number of brushings, brushing compliance (%), number of missed brushings, number of 
additional brushings over 3 weeks will be summarized using descriptive statistics.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 54 of 62 
Number of brushings is defin ed as: [(date of Visit  3 – date of Visit  2) multiplied by 2 – number 
of missing brushings + number of additional brushings].  
Brushing compliance (%) is defined as: [100 x (Number of brushings / Expected number of 
brushings)], where expected number of brus hings is defined as: [(date of Visit  3 – date of Visit  
2) multiplied by 2].  
[IP_ADDRESS]  Prior and Concomitant Medications  
Prior and Concomitant Medications will be listed only.  
12.3.6  Handling of Dropouts and Missing Data  
All m issing data for primary and secondary endpoints will be treated as missing data and not 
imputed. In the event that one of the hydrogen sulfide, methanethiol  or dimethyl sulfide  
concentrations are missing then the Total VSC will also be treated as missing.  
12.3.7  Interim Analysis  
No interim analysis is planned for this study . 
13 STUDY GOVERNANCE CONSIDERATIONS  
13.1 Quality Control  
In accordance with applicable regulations including GCP, and the sponsor’s  procedures, the 
sponsor or designee (i.e. third -party vendor) monitors will  contact [CONTACT_1200], study requirements, and their responsibilities 
to satisfy regulatory, ethical, and the sponsor’s  requirements.  
When reviewing data collection procedures, the disc ussion will include identification, 
agreement and documentation of data items for which the CRF will serve as the source 
document.  
The sponsor  or designee will monitor the study and site activity to verify that the:  
• Data are authentic, accurate, and comple te. 
• Safety and rights of subjects are being protected.  
• Study is conducted in accordance with the currently approved protocol and any other 
study agreements, GCP, and all applicable regulatory requirements.  
The extent and nature of monitoring will be descri bed in a written monitoring plan on file with 
the sponsor . The investigator (or designee) agrees to allow the monitor direct access to all 
relevant documents and agrees to co -operate with the monitor to ensure that any problems 
detected in the course of th ese monitoring visits are resolved.  
13.[ADDRESS_280199] a quality assurance assessment and/or audit of the site records, and the regulatory 
agencies may conduct  a regulatory inspection at any time during or after completion of the 
study.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 55 of 62 
In the event of an assessment, audit or inspection, the investigator (and institution) must agree 
to grant the advisor(s), auditor(s) and inspector(s) direct access to all relev ant documents and 
to allocate their time and the time of their staff to discuss the conduct of the study, any 
findings/relevant issues and to implement any corrective and/or preventative actions to address 
any findings/issues identified.  
The investigator(s ) will notify the sponsor  or its agents immediately of any regulatory 
inspection notification in relation to the study. Furthermore, the investigator will cooperate with 
the sponsor  or its agents to prepare the study site for the inspection and will allow the sponsor  
or its agent, whenever feasible, to be present during the inspection. The investigator will 
promptly apply copi[INVESTIGATOR_232163]. Before response 
submission to the regulatory authority, the investigator wi ll provide the sponsor  or its agents 
with an opportunity to review and comment on responses to any such findings.  
The sponsor will be available to help investigators prepare for an inspection.  
13.[ADDRESS_280200]/ Ethics Committee  
It is the responsibility of the investigator to have prospective approval of the study protocol, 
protocol amendments and informed consent documents, investigator brochure/safety statement 
(including any updates) and other relevant doc uments, e.g.  recruitment advertisements, if 
applicable, from the IRB/EC.  All correspondence with the IRB/EC should be retained in the 
investigator file.  Copi[INVESTIGATOR_1099]/EC approvals should be forwarded to the sponsor  prior to the 
initiation of the study, a nd also when subsequent amendments to the protocol are made.  
The only circumstance in which an amendment may be initiated prior to IRB/EC approval is 
where the change is necessary to eliminate apparent immediate hazards to the subjects.  In that 
event, the  investigator must notify the IRB/EC and the sponsor  in writing immediately after the 
implementation.  
13.3.[ADDRESS_280201] of the Study  
The study will be conducted in accordance with the protocol and legal and regulatory 
requirements, as well as the general principles set forth in the International Ethical Guidelines 
for Biomedical Research Involving Human Subjects (Council for Internation al Organizations 
of Medical Sciences 2002), International Ethical Guidelines for Health -Related Research 
Involving Humans (ICH, Nov 2016 ), guidelines for GCP (ICH, 1997 ), and the Declaration of 
Helsinki (World Medical Association, 2013 ).  
In addition, the study will be conducted in accordance with the protocol, the ICH guideline on 
GCP, and applicable local regulatory requirements and laws.  
13.3.[ADDRESS_280202] 
names, addresses, and other identifiable data will be replaced by [CONTACT_232197] a 
numbering system provided by [CONTACT_232198] -identify stu dy subjects .   Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280203]’s numerical code to his or her actual identity.  In case of data transfer, the sponsor  
will maintain high standards of confident iality and protection of subjects’ personal data 
consistent with applicable privacy laws.  
The informed consent documents must be in compliance with ICH GCP, local regulatory 
requirements, and legal requirements, including applicable privacy laws.  
The infor med consent documents used during the informed consent process must be reviewed 
and approved by [CONTACT_456], approved by [CONTACT_1201]/EC before use, and available for inspection.  
The investigator must ensure that each study subject,  is fully informed about the nature and 
objectives of the study and possible risks associated with participation.  
13.3.[ADDRESS_280204] Recruitment  
Advertisements approved by [CONTACT_1202]/ECs and investigator databases may be used as recruitment 
procedures.   Use of ethics committee approved, generic, pre screening questionnaire to assess 
basic subject characteristics to determine general eligibility for this study is allowed.   This 
generic questionnaire may be used by [CONTACT_1203] a phone script and/or to review internal databases 
to identify subjects.   
The s ponsor  will have an opportunity to review and approve the content of any study 
recruitment materials directed to potential study subjects before such materials are used.  
13.3.[ADDRESS_280205] 
research studies.  
In the event of any prohibition or restriction i mposed (i.e., clinical hold) by [CONTACT_1204], or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, the sponsor  should be informed immediately.  
In addition, the investigator will inform the sponsor  immediately of any urgent safety measures 
taken by [CONTACT_1205], and of any 
serious breaches of this protocol  or of ICH GCP that the investigator becomes aware of.  
13.[ADDRESS_280206] in the creation of knowledge and understanding  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : [ADDRESS_280207] the opportunity 
to review the complete study r esults at the sponsor’s  site or other mutually -agreeable location.  
The sponsor  will also provide the investigator with the full summary of the study results.  The 
investigator is encouraged to share the summary results with the study subjects, as appropria te. 
The procedures and timing for public disclosure of the results summary and for development of 
a manuscript for publication will be in accordance with the sponsor’s  Policy.  
A manuscript will be progressed for publication in the scientific literature if the results provide 
important scientific or medical knowledge.  
13.[ADDRESS_280208] maintain all site study records (except for 
those required by [CONTACT_1206]), in a safe an d secure location.   
The records (study/ site master file) must be maintained to allow easy and timely retrieval, when 
needed (e.g. for a sponsor  audit or regulatory inspection) and must be available for review in 
conjunction with assessment of the facilit y, supporting systems, and relevant site staff.  
Where permitted by [CONTACT_1207]/regulations or institutional policy, some or all of these records 
can be maintained in a format other than hard copy (e.g. microfiche, scanned, electronic); 
however, caution need s to be exercised before such action is taken.  
The investigator must ensure that all reproductions are legible and are a true and accurate copy 
of the original and meet accessibility and retrieval standards, including re -generating a hard 
copy, if required.  Furthermore, the investigator must ensure there is an acceptable back -up of 
these reproductions and that an acceptable quality control process exists for making these 
reproductions.  
The investigator must assure that the subject’s anonymity will be maintained.  On CRFs or other 
documents submitted to the sponsor , subjects should not be identified by [CONTACT_1208], 
but by [CONTACT_1209]. The investigator should keep a separate log of subjects’ codes, 
names and addresses.  Document s not for submission to the sponsor , e.g. subjects’ written 
consent forms, should be maintained by [CONTACT_1210].  
Records and documents, including signed ICF, pertaining to the conduct of this study must be 
retained by [CONTACT_232199], from the issue of the final 
Clinical Study Report (CSR) or equivalent summary,  unless local regulations or institutional 
policies require a longer retention period. The minimum retention time will meet the stric test 
standard applicable to that site for the study, as dictated by [CONTACT_1212], the sponsor’s  standards/procedures, and/or institutional requirements.   
No study document should be destroyed without a prior written agreement between the sponsor  
and the investigator. The investigator must notify the sponsor  of any changes in the archival 
arrangements, including, but not limited to, archival at an off -site facility or transfer of 
ownership of the records in the  event the investigator is no longer associated with the site.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 58 of 62 
13.7 Conditions for Terminating the Study  
Premature termination of this study may occur because of a regulatory authority decision, 
change in opi[INVESTIGATOR_1100]/EC, or study product safety problems , or at the discretion of the 
sponsor .  In addition, the sponsor retains the right to discontinue development of the 
experimental dentifrice at any time .  
If a study is prematurely terminated, the sponsor  will promptly notify the investigator.  After 
notif ication, the investigator must promptly contact [CONTACT_1213]/ follow -up for the subjects.  As directed by [CONTACT_456] , all study materials 
must be collected and all CRF’s completed to the greatest extent possible. Where required by 
[CONTACT_1214], the sponsor  should inform the regulatory authority(ies) 
and the investigator should promptly inform the IRB/EC and provide the IRB/EC a detailed 
written explanation of the termination or s uspension.  
If the IRB/EC terminates or suspends its approval/favorable opi[INVESTIGATOR_1101] a trial, the investigator 
should promptly notify the sponsor  and provide the sponsor with a detailed written explanation 
of the termination or suspension.  
Upon completion or  premature discontinuation of the study, the sponsor’s monitor will conduct 
site closure activities with the investigator or site staff, as appropriate, in accordance with 
applicable regulations including GCP, and the sponsor’s  Standard Operating Procedure s. 
14 REFERENCES  
[Abusleme L, Hoare A, Hong BY, et al. (2021)] Microbial signatures of health, gingivitis, and 
periodontitis. Periodontology 2000; 86(1): 57 -78. 
[ADA (2016)] Products Used in the Management of Oral Malodor.  
[ADA (2022)] Toothbrushes. https://www.ada.org/resources/research/science -and-research -
institute/oral -health -topi[INVESTIGATOR_1102]/toothbrushes : Extracte d 26 April 2022.  
[Allaker RP, Waite RD, Hickling J, et al. (2008)] Topographic distribution of bacteria 
associated with oral malodour on the tongue. Arch Oral Biol; [ADDRESS_280209] 1: S8 -S12. 
[Awano S, Gohara K, Kurihara E, et al. (2002)] The relationship between  the presence of 
periodontopathogenic bacteria in saliva and halitosis. Int. Dent. J.; 52(S5P1): 212 -6. 
[Bosma ML, Besho RW, Walley D, et al. (1997)] Clinical efficacy of an optimized stannous 
fluoride dentifrice, Part 5: A [ADDRESS_280210] [LOCATION_003]. 
Compend Contin Educ Dent; 18 Spec No: 24 -7. 
[Burnett GR, Stephen AS, Pi[INVESTIGATOR_232164], et al. (2011)] In vitro effects of novel toothpaste actives 
on components of oral malodour. 61: 67 -73. 
[Calil C, Lima P, Bernardes C, et al. (2008)] I nfluence of gender and menstrual cycle on 
volatile sulphur compounds production. Archives of oral biology; 53(12): 1107 -12. 
[Chapple ILC, Mealey BL, Van Dyke TE, et al. (2018)] Periodontal health and gingival 
diseases and conditions on an intact and a redu ced periodontium: Consensus report of 
workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri -
Implant Diseases and Conditions. J Clin Periodontol; [ADDRESS_280211] 20: S68 -S77. 
[Chen X, Zhang Y, Lu H -X, et al. (2016)] Factors associate d with halitosis in white -collar 
employees in Shanghai, China. PloS one; 11(5): e0155592.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 59 of 62 
[Dadamio J, Laleman I, De Geest S, et al. (2013)] Usefulness of a new malodour -compound 
detection portable device in oral malodour diagnosis. Journal of Breath Resear ch; 7(4): 
046005.  
[De Geest S, Laleman I, Teughels W, et al. (2016)] Periodontal diseases as a source of 
halitosis: a review of the evidence and treatment approaches for dentists and dental hygienists. 
Periodontology 2000; 71(1): 213 -27. 
[FDA (2003)] Oral Health Care Drug Products for Over the -Counter Human Use; 
Antigingivitis/ Antiplaque Drug Products; Establishment of a Monograph; Proposed Rules.  
[Ganss C, Schlueter N, Preiss S, et al. (2009)] Tooth brushing habits in uninstructed adults —
frequency, techni que, duration and force. Clinical oral investigations; 13(2): 203 -8. 
[Gerlach R, Hyde J, Poore C, et al. (1998)] Breath effects of three marketed dentifrices: a 
comparative study evaluating single and cumulative use. J. Clin. Dent.; 9(4): 83 -8. 
[ICH (1997) ] GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8.  
[ICH (Nov 2016)] Topic E6 (R2) Guideline for Good Clinical Practice.  
[Macgregor ID, Rugg ‐Gunn AJ (1985)] Too thbrushing duration in 60 uninstructed young 
adults. Community dentistry and oral epi[INVESTIGATOR_623]; 13(3): 121 -2. 
[Machtei EE, Mahler D, Sanduri H, et al. (2004)] The effect of menstrual cycle on periodontal 
health. Journal of periodontology; 75(3): 408 -12. 
[Makin SA (2013)] Stannous fluoride dentifrices. Am. J. Dent.; 26: 3A -9A. 
[Mallatt M, Mankodi S, B auroth K, et al. (2007)] A controlled 6 ‐month clinical trial to study 
the effects of a stannous fluoride dentifrice on gingivitis. Journal of clinical periodo ntology; 
34(9): 762 -7. 
[Mankodi S, Bartizek RD, Leslie Winston J, et al. (2005)] Anti ‐gingivitis e fficacy of a 
stabilized 0.454% stannous fluoride/sodium hexametaphosphate dentifrice. Journal of clinical 
periodontology; 32(1): 75 -80. 
[Murata T, Rahardjo A, Fujiyama Y, et al. (2006)] Development of a Compact and Simple 
Gas Chromatography for Oral Malodo r Measurement. Journal of Periodontology; 77(7): 
1142 -7. 
[Nehme M, Mason S, Hughes N, et al. (2013)] A randomized clinical study investigating the 
staining profile of an experimental stannous fluoride dentifrice. Am. J. Dent.; 26: 32A -8A. 
[Newby [CONTACT_232200], Hickli ng JM, Hughes FJ, et al. (2008)] Control of oral malodour by [CONTACT_232201]. Arch Oral Biol; [ADDRESS_280212] 1: S19 -25. 
[Oho T, Yoshida Y, Shimazaki Y, et al. (2001)] Characteristics of patients complaining of 
halitosis and the usefuln ess of gas chromatography for diagnosing halitosis. Oral Surgery, 
Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology; 91(5): 531 -4. 
[Paraskevas S, Van der Weijden G (2006)] A review of the effects of stannous fluoride on 
gingivitis. J. Clin. Periodontol.; 33(1): 1 -13. 
[Parkinson C, Amini P, Wu J, et al. (2018a)] A 24 -week randomized clinical study 
investigating the anti -gingivitis efficacy of a 0.454% w/w stannous fluoride dentifrice. Am. J. 
Dent.; 31(1).  
[Parkinson C, Hughes N, Jeffery P, et al. (2013)] The efficacy of an experimental dentifrice 
containing 0.454% w/w stannous fluoride in providing relief from the pain of dentin 
hypersensitivity: an 8 -week clinical study. Am. J. Dent.; 26: 25A -31A.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 60 of 62 
[Parkinson CR, Amini P, Jose A, et al. (2018b) ] A 12 -week randomized clinical study 
investigating the anti -gingivitis efficacy of a 0.454% w/w stannous fluoride dentifrice. Am. J. 
Dent.; 31(2): 81 -5. 
[Parkinson CR, Hughes N, Hall C, et al. (2016)] Three randomized clinical trials to assess the 
short -term efficacy of anhydrous 0.454% w/w stannous fluoride dentifrices for the relief of 
dentin hypersensitivity. Am. J. Dent.; 29(1): 25 -32. 
[Parkinson CR, Jeffery P, Milleman JL, et al. (2015)] Confirmation of efficacy in providing 
relief from the pain of de ntin hypersensitivity of an anhydrous dentifrice containing 0.454% 
with or without stannous fluoride in an 8 -week randomized clinical trial. Am. J. Dent.; 28(4): 
190-6. 
[Payne D, Gordon JJ, Nisbet S, et al. (2011)] A randomised clinical trial to assess con trol of 
oral malodour by a novel dentifrice containing 0.1% w/wo ‐cymen‐5‐ol, 0.6% w/w zinc 
chloride. International dental journal; 61: 60 -6. 
[Pham TAV, Ueno M, Zaitsu T, et al. (2011)] Clinical trial of oral malodor treatment in 
patients with periodontal d iseases. Journal of periodontal research; 46(6): 722 -9. 
[Rizzo AA (1967)] The possible role of hydrogen sulfide in human periodontal disease. I. 
Hydrogen sulfide production in periodontal pockets. Periodontics; 5(5): 233 -6. 
[Rølla G, Ellingsen J (1994)] Clinical effects and possible mechanisms of action of stannous 
fluoride. Int. Dent. J.; 44([ADDRESS_280213] 1): 99 -105. 
[Rosenberg M, Kulkarni G, Bosy A, et al. (1991a)] Reproducibility and sensitivity of oral 
malodor measurements with a portable sulphide monitor. J. Dent. Res; 70(11): 1436 -40. 
[Rosenberg M, Septon I, Eli I, et al. (1991b)] Halitosis measurement by [CONTACT_232202]. Journal of periodontology; 62(8): 487 -9. 
[Rösing CK, Loesche W (2011)] Halitosis: an overview of epi[INVESTIGATOR_623], etiology a nd clinical 
management. Brazilian oral research; 25(5): 466 -71. 
[Samant A, Malik C, Chabra S, et al. (1976)] Gingivitis and periodontal disease in pregnancy. 
47(7): 415 -8. 
[Schmidt NF, Tarbet WJ (1978)] The effect of oral rinses on organoleptic mouth odor ratings 
and levels of volatile sulfur compounds. Oral Surgery, Oral Medicine, and Oral Pathology; 
45(6): 876 -83. 
 (2010)] Effect of An Experimental Toothpaste on Bad Breath, [COMPANY_004] data on file  
 (2011)] Experimental gel -to-foam dentifrice co ntaining 0.6%w/w zinc chloride, 
[COMPANY_004] data on file  
[Tangerman A, Winkel E (2008)] The portable gas chromatograph OralChroma™: a method 
of choice to detect oral and extra -oral halitosis. Journal of breath research; 2(1): 017010.  
[Tonzetich J, Preti G, Huggins  GR (1978)] Changes in concentration of volatile sulphur 
compounds of mouth air during the menstrual cycle. Journal of International Medical 
Research; 6(3): 245 -54. 
[Twetman S, Axelsson S, Dahlgren H, et al. (2003)] Caries ‐preventive effect of fluoride 
toothpaste: a systematic review. Acta Odontologica Scandinavica; 61(6): 347 -55. 
[US FDA (2005)] GUIDANCE FOR INDUSTRY: COLLECTION OF RACE AND 
ETHNICITY DATA IN CLINICAL TRIALS.  Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
CCI
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 61 of 62 
[Van den Broek AM, Feenstra L, de Baat C (2007)] A review of the current literature on 
aetiology and measurement methods of halitosis. Journal of dentistry; 35(8): 627 -35. 
[Vandekerckhove B, Van den Velde S, De Smit M, et a l. (2009)] Clinical reliability of non ‐
organoleptic oral malodour measurements. J. Clin. Periodontol.; 36( 11): 964 -9. 
[Washio J, Sato T, Koseki T, et al. (2005)] Hydrogen sulfide -producing bacteria in tongue 
biofilm and their relationship with oral malodour. Journal of medical microbiology; 54(9): 
889-95. 
[Winkel E, Roldan S, Van Winkelhoff AJ, et al. (2003)] Clinical effects of a new mouthrinse 
containing chlorhexidine, cetylpyridinium chloride and zinc ‐lactate on oral halitosis: A 
dual‐center, double ‐blind placebo ‐controlled study. J. Clin. Periodontol.; 30(4): 300 -6. 
[World Medical Association (2013)] Declar ation of Helsinki, 64th General Assembly, 
Fortaleza.  
[Young A, Jonski G, Rölla G, et al. (2001)] Effects of metal salts on the oral production of 
volatile sulfur ‐containing compounds (VSC). J. Clin. Periodontol.; 28(8): [ADDRESS_280214] USE  
Brush twice a day (morning and evening).  
Each time you brush:  
• Dispense a ribbon of toothpaste covering the length of the toothbrush head (see below 
pi[INVESTIGATOR_1103]).  Only the supplied toothbrush may be used.  
• Set your timer for 1 minute, and then brush your teeth in your usual manner for 1 timed 
minute.  
 
 
 
• Record each brushing  on the diary card . Note any changes to these brushing procedures 
and reasons for changes (e.g. missed brushings, extra brushings) in the ‘Comments’ 
column.  
Protocol  17 Sep 2022 | TMF-238323 | 2.0
CCI
[COMPANY_004] Consumer Healthcare   
Clinical Protocol    
Protocol Number : 300025  
 
Property of [COMPANY_004] Consumer Healthcare  - Confidential   
May not be used, divulged, p ublished or otherwise disclosed without the consent of [COMPANY_004] CH 
 Clinical Protocol Template v 9.0 
Page 62 of 62 
• Record any changes in your smoking habits, health, medications (prescription and over 
the counter medications) , or treatments  on the diary card.  
• Bring your diary  card (completed and not completed) , toothpaste and toothbrush to the 
next study visit.  
 
15.[ADDRESS_280215]  European Clinical Trials Database  
FDA Food and Drug Administration ([LOCATION_002])  
GCP  Good Clinical Practice  
HIV human immunodeficiency virus  
ICH International Conference on Harmonisation  
ID identification  
IRB institutional review board  
IRC internal review committee  
LSLV  last subject last visit  
MedDRA  medical Dictionary for Regulatory Activities  
N/A not applicable  
PI [INVESTIGATOR_232165]  17 Sep 2022 | TMF-238323 | 2.0
CCI
Signature [CONTACT_1219]  300025 TMF-238323 v2.0
Signature [CONTACT_1220]-238323 v2.0Reason for signing: Approved Name: 
[CONTACT_1221]: A
nature: Protocol  17 Sep 2022 | TMF-238323 | 2.0
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]